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Abbreviations 
ABTS   a substrate of enzyme horseradish peroxidase 
ADAM   a disintegrin and metalloprotease 
bFGF   basic fibroblast growth factor 
BBB   blood brain barrier 
BRB   blood retina barrier 
COUP-TFII  COUP transcription factor 2 
Ca2+   calcium 
CD   cluster of differentiation 
CD99L2  CD99 antigen-like protein 2 
Dll4   delta-like 4 
EC   endothelial cells 
ECM   extracellular matrix 
ERK   extracellular signal-regulated kinases 
Eph named after erythropoietin-producing human hepatocellular 
carcinoma cell line 
Ephrin  Eph family receptor in
ESAM   endothelial cell-selective adhesion molecule 
teracting proteins 
ESL1   E-selectin ligand 1 
FAK   focal adhesion kinase 
FGFR   fibroblast growth factor receptor 
FITC   fluorescein isothiocyanate 
FoxO1  forkhead box O1 
GRIP   glutamate receptor-interacting protein 1 
GPI   glycosylphosphatidylinositol 
Grb   growth factor receptor-bound protein 
GM-CSF  granulocyte/macrophage colony-stimulating factor 
HUVECs  human umbilical vein endothelial cells 
IL   interleukin 
IFNγ   interferon-γ 
ICAM-1  intercellular adhesion molecule-1 
ICAM-2  intercellular adhesion molecule-2 
JAM    junctional adhesion molecule 
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Jak   Janus kinase 
JNK   c-Jun N-terminal kinases 
LPS   lipopolysaccharides 
LFA-1   lymphocyte function-associated antigen-1 (αLβ2-integrin) 
LBRC   lateral border recycling compartment 
MAC-1  macrophage antigen-1 
MAC-3  macrophage antigen (CD107b) 
MCP-1  monocyte chemoattractant protein-1 
MLC   myosin light chain 
MLCK   myosin light chain kinase 
MLCP   myosin light chain phosphatase  
Nck   non-catalytic region of tyrosine kinase adaptor protein 1 
NO   nitric oxide 
PSGL1  P-selectin glycoprotein ligand 1 
PDGFR  platelet-derived growth factor receptor 
PTP-BL  tyrosine-protein phosphatase non-receptor type 13 (PTPN13) 
PI3K   phosphoinositol 3-kinase 
PECAM-1  platelet/endothelial cell adhesion molecule-1 
Par   partitioning defective 
PDZ   PSD95/Discs-large/ZO1 
PEI   polyethylenimine 
RGS3   regulator of G-protein signaling 3 
ROCK  rho-associated protein kinase 
Rac   Ras-related C3 botulinum toxin substrate 
SHP2   SH2 domain-containing phosphatase 2 
SH2   Src homology 2 
SDF-1  stromal cell-derived factor 1 
Shh   sonic hedgehog 
STAT   signal transducer and activator of transcription 
SMC   smooth muscle cells 
Tie2 tyrosine kinases that contain immunoglobulin-like loops and 
epidermal growth factor-similar domains 2 
TNFα   tumor necrosis factor α 
VEGF   vascular endothelial growth factor 
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VEGFR  vascular endothelial growth factor receptor 
VE-PTP  vascular endothelial protein tyrosine phosphatase 
VCAM-1  vascular cell adhesion molecule-1 
vWF   von Willebrand factor 
VLA-4   very late antigen-4 (α4β1-integrin) 
ZO   zonula occludens 
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ZUSAMMENFASSUNG 
Ein zentraler Punkt in der stark regulierten Entwicklung des Gefäßsystems ist die 
Bindung der membran-assoziierten EphrinB-Liganden an ihren 
korrespondierenden Rezeptor EphB in Endothelzellen (EZ). Bisher ist jedoch nur 
wenig über die Funktion des EphrinB/EphB-Systems in adulten Blutgefäßen 
bekannt. Wir haben in diesem Zusammenhang beobachtet, dass die Liganden 
EphrinB1 und EphrinB2 auf der Oberfläche von EZ lokalisiert sind und ihre 
Expression im Verlauf inflammatorischer Prozesse zunimmt, während EphB2-
Rezeptoren konstitutiv auf Monozyten exprimiert werden. Insofern stellten wir die 
Hypothese auf, dass diese Liganden unter pro-inflammatorischen Bedingungen an 
EphB-Rezeptoren auf Monozyten binden. Um die funktionellen Konsequenzen der 
Rezeptor-Liganden-Interaktion zu untersuchen, wurden kultivierte EZ gegenüber 
EphB2-Rezeptorkörpern oder EphB2-Rezeptor überexprimierenden Maus-
Myelom-Zellen exponiert und die Expression von EphrinB1 bzw. EphrinB2 in den 
EZ mittels siRNA herunterreguliert.  
Ausgehend von diesem experimentellen Aufbau wurde die pro-inflammatorische 
Differenzierung der EZ und die Migration von Monozyten durch einen EZ-
Monolayer analysiert. Die vorwärtsgerichtete, nachgeschaltete Signalgebung von 
EphB-Rezeptoren förderte die Aktivierung von Monozyten. Die rückwärtsgerichtete 
EphrinB-Signalgebung hingegen, induzierte den Abbau des von Willebrand-
Faktors auf der Oberfläche der EZ, verstärkte die Expression von E-Selektin, 
VCAM-1 und des Granulozyten-Makrophagen-Kolonie-stimulierenden Faktors 
(GM-CSF)  und stimulierte dadurch die Adhäsion von Monozyten. Dabei zeigte 
sich, dass die Expression beider Liganden für die Migration der Monozyten durch 
den EZ-Monolayer essentiell ist. Die Aktivierung der Monozyten durch EphB2 
wurde von einem Rückgang der Integrität der Zell-Zell-Verbindungen zwischen 
den EZ begleitet. Dies wurde nicht nur durch Src-abhängige Phosphorylierung von 
PECAM-1 und eine  Verminderung der SHP-2 Aktivität vermittelt, sondern auch 
durch die Verdrängung von VE-Cadherin aus den interendothelialen Zellkontakten. 
Zudem erhöhte die Stimulation mit EphB2 die Permeabilität der EZ. Die 
endothelzellspezifische Unterdrückung der EphrinB2 Expression in vivo wurde 
durch die Injektion von Tamoxifen in Tie2-CreERT2xephrinB2flox/flox Mäusen 
induziert. Es wurden vier verschiedene Entzündungsmodelle verwendet, um die 
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Rolle von EphrinB2 bei der Monozyten-Diapedese und die pro-inflammatorische 
EZ-Antwort in vivo zu analysieren: das TPA induzierte Ohr-Ödem, die Thioglykolat 
vermittelte Peritonitis, die ApoE-Defizienz-vermittelte Arteriosklerose, sowie das 
Hinterlauf-Ischmämie Modell. Allerdings deuteten die Ergebnisse aller vier 
Mausmodelle daraufhin, dass der Verlust der mikrovaskulären endothelialen 
EphrinB2-Expression keine signifikanten Auswirkungen auf die die Monozyten-
Infiltration, den Entzündungsverlauf bzw. Schweregrad oder die Progression der 
Arteriogenese hat. Diese Befunde könnten auf bestimmte Limitationen der 
verwendeten Mausmodelle hinweisen oder auf einen kompensatorischen Effekt 
von EphrinB1 bei EphrinB2-Verlust zurückzuführen sein.Insgesamt deuten unsere 
Daten zum ersten Mal daraufhin, dass das EphrinB/EphB-System zu den 
inflammatorischen Reaktionen der EZ beiträgt, wobei die rückwärtsgerichtete 
EphrinB-Signalgebung die Adhäsion und Transmigration von EphB2-
exprimierenden Monozyten unterstützt und die Permeabilität der EZ erhöht. 
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SUMMARY 
The binding of membrane-associated ephrinB ligands to corresponding EphB 
receptors in endothelial cells (ECs) is pivotal for orchestrating the development of 
the circulatory system. However, only little is known about their function in adult 
blood vessels. In this context, we observed that the ligands ephrinB1 and ephrinB2 
are localized on the surface of ECs where their expression is upregulated during 
inflammation, while EphB2 receptors are located on the surface of monocytes. 
Consequently, we hypothesized that these ligands bind to EphB receptors 
expressed in monocytes under pro-inflammatory conditions. To study functional 
consequences of their ligand-receptor interactions, ECs were exposed to EphB2 
receptor bodies or EphB2-overexpressing mouse myeloma cells upon siRNA-
mediated knockdown of ephrinB1 or ephrinB2. 
Based on this experimental setup, we analyzed the pro-inflammatory 
differentiation of the ECs and the transmigration of monocytes through the EC 
monolayer. Whereas forward signaling downstream of the EphB receptors 
promotes activation of monocytes, ephrinB reverse signaling induces the 
deposition of von Willebrand factor on the ECs surface, increases the expression 
of E-selectin, VCAM-1 and granulocyte-macrophage colony-stimulating factor in 
ECs, and consequently stimulates monocyte attachment. Moreover, ephrinB1 and 
ephrinB2 are crucial for the transmigration of monocytes through the endothelial 
cell monolayer. Their activation by EphB2 not only promotes PECAM-1 
phosphorylation through a Src-dependent mechanism while diminishing SHP-2 
activity, but also triggers displacement of VE-cadherin from interendothelial cell 
junctions. In addition, EphB2 stimulation increases the permeability of endothelial 
cells. In vivo, endothelial cell specific ephrinB2 ablation was induced by injecting 
tamoxifen in Tie2-CreERT2/ephrinB2flox/flox mice. Three distinct types of 
inflammatory models-TPA-induced ear edema, thioglycollate-elicited peritonitis, 
atherosclerosis, as well as an arteriogenesis model were employed to analyze the 
impact of ephrinB2 on monocyte extravasation and progression of pathological 
processes. However, all four models indicated that loss of endothelial ephrinB2 
has no impact on monocyte infiltration, inflammatory pathology, and progression of 
arteriogenesis. This might be due to the limitations of the utilized models and 
compensatory effects of ephrinB1. Collectively, our data indicates for the first time 
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that the EphB/ephrinB system contributes to inflammatory responses of ECs 
whereby ephrinB reverse signaling supports adhesion and transmigration of 
EphB2-expressing monocytes, and increases endothelial cell permeability. 
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1 INTRODUCTION 
1.1 General organization of the vessel wall  
The vascular system is a complex network of blood vessels (arteries, arterioles, 
veins, venules, capillaries) to maintain the circulation of blood flow, which is critical 
for cell homeostasis by providing nutrients and disposing cellular waste. The wall 
of both veins and arteries can be divided into three layers: the intima (endothelial 
cells attached to the basement membrane), the media (smooth muscle cells and 
elastin fibers), and the adventitia (fibro-elastic connective tissue). This general 
structure can vary widely. For instance, the capillaries consist of a monolayer of 
endothelial cells, basement membrane, and some pericytes, whereas arterioles 
and large venules contain at least one layer of smooth muscle cells and some 
connective tissues [1]. 
 
1.1.1 Characteristics of endothelial cells in the vascular system 
The endothelium, lining the inner surface of blood and lymphatic vessels, has 
diverse functions, including maintenance of endothelial barrier, leukocyte 
trafficking, angiogenesis, as well as regulation of vasodilation and thrombolysis [2, 
3]. Depending on the epigenetic determination and various microenvironmental 
cues, including biomechanical forces (shear stress and cyclic strain) and 
biochemical stimulators (e.g. growth factors, cytokines, chemokines, hormones, 
etc.), endothelial cell phenotypes vary widely. This is referred to as endothelial cell 
heterogeneity [4]. For instance, endothelial cell thickness is less than 0.1 µm in 
capillaries and veins, and up to 1 µm in the aorta [5]. Moreover, the composition of 
intercellular junctions is different as well. Tight junctions between adjacent 
endothelial cells are well-organized in precapillary arterioles, whereas in 
postcapillary venules, tight junctions are discontinuous and loose, which is suitable 
for leukocyte extravasation [6]. 
 
1.1.2 Ways of blood vessel formation and remodeling  
The formation of blood vessels starts at the early phase of embryonic development 
through two distinct processes: vasculogenesis and angiogenesis. Additionally, 
arteriogenesis is an adaptive process of transforming pre-existing arterioles into 
functional arteries under the condition of ischemia [7]. 
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1.1.2.1  Angiogenesis 
Angiogenesis is defined as the formation of new capillaries from pre-existing 
capillary networks both in embryos and adults, which could be accomplished by 
endothelial sprouting and non-sprouting angiogenesis. Sprouting angiogenesis 
involves the specialization of endothelial cells (tip cells, stalk cells and phalanx 
cells), the interplay of various signaling pathways (e.g. Notch and Notch ligands, 
VEGF and VEGFRs), and processes of vascular maturation and stabilization (e.g. 
lumen formation and perfusion, network formation, remodeling, pruning, 
association with mural cells) [8, 9]. Moreover, arteriovenous differentiation is a 
crucial process to form arteries and veins in early embryonic development. 
Activation of the Shh/VEGFA/Notch pathway stimulates the expression of 
ephrinB2 to function as artery identity. Whereas, COUP-TFII suppresses the Notch 
signaling to induce the expression of EphB4 in the venous endothelium [9, 10]. 
Besides sprouting, non-sprouting angiogenesis or intussusception is an alternative 
way to expand vascular networks. In this process, existing blood vessels are 
divided by invagination and formation of transluminal pillars [11]. 
 
1.1.2.2  Arteriogenesis 
Arteriogenesis is characterized by the remodeling of pre-existing small arterioles 
into much larger conductance arteries [12]. It is triggered mainly by an elevation of 
shear stress, which is induced by increased blood flow following the occlusion of a 
conduit artery [13]. Several mechanical sensors on endothelial cells (e.g. integrin, 
ion channels etc.) are responsible for transferring mechanical stimuli into the 
intracellular signaling. This leads to the activation of endothelial cells, such as the 
upregulation of adhesion molecule expression, chemokine and NO release, as 
well as increased permeability [14]. Meanwhile, smooth muscle cells proliferate, 
migrate, and change from a contractile to a synthetic phenotype [13]. Furthermore, 
perivascular macrophages secrete various growth factors (e.g. bFGF), cytokines 
(e.g. TNFα), and proteases, and thus contribute to vascular wall remodeling [15]. 
Eventually, these molecular and cellular events result in the remodeling of 
collateral arterioles, including the enlargement of vessel lumen and an increase in 
wall thickness. This process generates functional arteries which are capable of 
restoring blood flow in ischemic tissue where a conduit artery is occluded [16]. 
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1.2 Inflammation and immune cells 
Inflammation is an initial reaction of the immune system in response to infection, 
irritation or injury. The classical signs of acute inflammation are pain, heat, 
redness, swelling, and loss of function. Persistent pro-inflammatory stimuli lead to 
chronic inflammation which is related to progression of diverse diseases such as 
atherosclerosis, arthritis and Alzheimer’s disease [17]. Alterations in 
microcirculation during inflammation contain vasodilation, vascular leakage and 
increased blood flow [18]. Another hallmark of this process is the recruitment of 
leukocytes to the inflamed site, which mainly occurs in postcapillary venules [19]. 
Leukocytes are classified as polymorphonuclear (granulocytes) and mononuclear 
(agranulocytes) cells according to the appearance of nuclei and the presence of 
granules in their cytoplasm. Granulocytes consist of neutrophils, eosinophils and 
basophils. Agranulocytes include monocytes and lymphocytes [20]. Apart from 
immune cells, cell- or plasma-derived soluble inflammatory mediators, including 
histamine, platelet activating factor, cytokines, chemokines, complement and 
ROS, play a role in diverse pathological responses during inflammation, such as 
vasodilation, chemotaxis, tissue damage and pain [21]. 
 
1.3  Leukocyte extravasation 
Leukocyte extravasation is a critical process in inflammation and immune 
surveillance. The cascade of leukocyte extravasation has been subdivided into 
sequential steps: tethering and rolling, activation, firm adhesion, para- and 
trans-cellular transmigration, and migration through the basal membrane (Figure 
1) [19]. In fact, most leukocytes which attach to inflamed postcapillary venules 
return to circulation since their adhesion is reversible. Penetration of the 
endothelial barrier is an irreversible step in leukocyte extravasation [22]. 
 
1.3.1 Leukocyte adhesion 
The initial procedure for leukocyte recruitment is the adhesion of these cells to the 
endothelium. This is accomplished by sequential and overlapping steps, including 
selectin-mediated rolling, arrest chemokines-mediated activation of leukocyte 
integrins and integrin-mediated firm adhesion [22]. 
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Trans-cellular
1.Tethering 
and Rolling 2.Activation 3.Firm adhesion 
Para-cellular
4.Transmigration
Blood flow
1.Selectins
3.Integrins and adhesion molecules
2.Chemokines
Leukocytes
Endothelial 
cells
4.PECAM-1, ESAM, JAMs, CD99
Basal membrane
 
 
Figure 1: The cascade of leukocyte extravasation. 
Multiple steps and key molecules involved in leukocyte extravasation are displayed. Circulating 
leukocytes are captured by selectins, which initiate leukocyte rolling on endothelium. Exposure to 
chemokines on endothelial cells activates leukocyte integrins. Firm adhesion is mediated by the 
interactions of fully activated integrins and adhesion molecules. Leukocytes transmigrate through 
the endothelial cell monolayer via either a paracellular or transcellular route (adapted from Ley K 
2007). 
 
Selectins, comprising P-selectin, L-selectin and E-selectin, interact with P-selectin 
glycoprotein ligand 1 (PSGL1), glycosylated CD44 and E-selectin ligand 1 (ESL1) 
expressed in most leukocytes [22]. This binding mediates leukocyte capture 
(tethering) and sequent rolling along the endothelium to slow down their velocity 
[23]. Furthermore, rolling of leukocytes allows their binding to arrest chemokines 
that are deposited on the luminal surface of inflamed endothelial cells, including 
CXCL12, CCL21, CXCL1, CCL2 and CCL25 [24]. These immobilized chemokines 
interact and activate G-protein coupled chemokine receptors (GPCR) on the 
leukocyte surface, which induces intracellular signaling and thereby promoting 
rapid integrin activation [25]. 
Firm adhesion of leukocytes is achieved by the binding of their fully activated 
integrins with the corresponding receptors-Immunoglobulin (Ig) superfamily of 
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adhesion molecules in endothelial cells. Pro-inflammatory mediators (e.g. TNF-α, 
IL-1β) induce an increased expression of adhesion molecules in endothelial cells 
[19, 26]. VCAM-1 interacts with the integrin VLA4. ICAM-1 binds to the integrins 
LFA-1 and Mac-1 [27]. Moreover, LFA-1 and Mac-1 have distinct roles in leukocyte 
arrest. While LFA-1 initiates leukocyte adhesion, Mac-1 mediates intraluminal 
crawling which allows leukocytes to search for the optimal sites of emigration [28, 
29]. 
 
1.3.2 Leukocyte diapedesis 
Once leukocytes crawl to the preferred sites, transendothelial migration or 
diapedesis occurs, which is accomplished by either a trans- or para-cellular route 
[19]. The trans-cellular migration is a process that allows leukocytes to pass 
through the endothelial cytoplasm via vesicular/canalicular systems [30]. The 
usage of this route is particularly predominant in leukocyte transmigration through 
blood brain barrier (BBB) and blood retinal barrier (BRB), because of the 
extremely tight junctions between adjacent endothelial cells [31]. Most diapedesis 
takes place via the para-cellular route, in which leukocytes extend pseudopods 
and squeeze through the endothelial cell borders. A bunch of molecules enriched 
at intercellular junctions, including PECAM-1, ICAM-2, ESAM, CD99, CD99L2 and 
JAMs, synergetically cooperate to control leukocyte para-cellular transmigration. In 
addition, ICAM-1 and VCAM-1 play a role in this process as well [32]. 
The main processes in leukocyte para-cullular transmigration are indicated in the 
following three aspects. First, leukocyte adhesion evokes clustering of ICAM-1 and 
VCAM-1 on the endothelial cell surface, which is referred to as “docking 
structures” or “transmigratory cups” [33, 34]. Second, the loosening of intercellular 
junctions is a prerequisite for leukocyte transmigration. The reversible formation of 
gaps is driven by VE-cadherin displacement [35-37]. Phosphorylation of specific 
tyrosine sites of VE-cadherin is required for this process, as indicated in chapter 
1.4.1 [38, 39]. Moreover, downstream signaling pathways of clustered ICAM-1 and 
VCAM-1 result in endothelial cell contraction and thus weaken intercellular 
junctions [40-42]. Third, leukocyte transmigration requires targeted membrane 
recycling from the lateral border recycling compartment (LBRC) [43]. The LBRC is 
composed of 50 nm vesicle-like structures connected to each other, which 
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localizes just beneath the lateral plasma membrane. The compartment contains 
PECAM-1, JAM-A, and CD99 (Figure 2) [44]. In resting endothelial cells, the 
membrane traffics constitutively between the lateral plasma membrane and the 
LBRC. Once a leukocyte crosses the endothelium, LBRC membrane is trafficked 
to the site of diapedesis and surrounds the leukocyte, which is required for the 
leukocyte transmigration [44, 45]. 
 
1.4 Permeability  
Increased microvascular permeability, a hallmark of inflammation, occurs in a 
variety of human pathological conditions, such as ischemia-reperfusion injury, 
stroke, sepsis and acute respiratory distress syndrome [46]. Diverse mediators, 
including permeability-increasing factors (e.g. thrombin, histamine, bradykinin, 
VEGF), oxidants, prostanoids, ischemia and pro-inflammatory stimuli (e.g. TNFα), 
play a role in regulating endothelial permeability [46]. Indeed, endothelial 
permeability is achieved by either a trans- or para-cellular pathway. During the 
trans-cellular route, the substance passes through cell bodies by channels, 
carriers, pumps or vesicles; in the para-cellular route, it crosses cell-cell contacts 
via loose intercellular junctions [47]. Impairment of the endothelial barrier not only 
allows the transport of plasma proteins, solutes, and fluid, resulting in oedematous 
tissue injury, but also favors leukocyte transmigration [48]. 
Endothelial cell-cell contacts are composed of two types of adhesive structures, 
namely adherens junctions (AJs) and tight junctions (TJs), which maintain the 
endothelial barrier (Figure 2). Adherens junctions contain VE-cadherin and its 
binding partners [49]. Tight junctions consist of membrane proteins (claudins, 
occludin, JAM family, ESAM, CD99) and other cytoplasmic components (ZO 
proteins and others), which are particularly enriched in stringent barriers such as 
BBB and BRB [50]. Of note, AJs and TJs are regulated mutually. Clustering of VE-
cadherin upregulates the expression of claudin-5 through limiting nuclear 
translocation of the forkhead transcriptional repressor FoxO1–β-catenin complex 
[51]. Vice versa, JAM-C modulates VE-cadherin-mediated adhesion, as loss of 
JAM-C increases homophilic adhesive interactions of VE-cadherin dependent on 
Rap1 [52]. 
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Figure 2: Key molecules in the endothelial cell-cell contacts. 
Adherens junctions are composed of VE-cadherin and its binding partner-p120-catenin, β-catenin, 
and γ-catenin. Tight junctions include claudins (3, 5, 12), occludin, members of the JAM family, 
ESAM, and cytoplasmic proteins (e.g. ZO proteins). CD99, PECAM-1 and JAM-A are components 
of the lateral border recycling compartment (adapted from Daniel AE 2013). 
 
1.4.1 Vascular endothelial (VE)-cadherin 
VE-cadherin belongs to the cadherin family. It is a transmembrane protein whose 
cytoplasmic domain interacts with p120-catenin, β-catenin and γ-catenin. These 
adherens junction components are associated with actin-binding proteins (e.g. 
α-catenin, vinculin), phosphatases (e.g. VE-PTP), kinases (e.g. src, csk) and 
growth factor receptors (e.g. VEGFR2 and TGFβ receptor) [48]. VE-cadherin is 
required for maintaining vascular integrity, and thus controls vascular permeability 
and represents a barrier for leukocyte extravasation [53]. Functional blockade of 
VE-cadherin induces an increase in blood vessel permeability, accompanied by 
the migration of distinct leukocyte subsets [54, 55]. Dismantling of VE-cadherin on 
the cell surface is accomplished by phosphorylation, internalization and cleavage 
[56]. 
Diverse permeability-increasing mediators induce VE-cadherin phosphorylation at 
specific residues, Y658, Y685, Y731 and S665, which is mediated by Src family 
kinases [49, 53, 57-60]. This leads to VE-cadherin internalization and the 
                                                                                                           Introduction 
 
15 
 
disassembly of the adherens junction complex [49, 60]. It has recently been 
reported that veins but not arteries display constitutive and prolonged 
phosphorylation of Src, Y658 and Y685 of VE-cadherin. This may sensitize veins 
to permeability-inducing agents, resulting in rapidly reversible openings of 
endothelial cell junctions [49]. Moreover, internalization of VE-cadherin occurs in a 
clathrin-dependent manner [60, 61]. VE-cadherin cleavage is accomplished by 
leukocytes- or tumor cells-released enzymes digesting the extracellular part of 
VE-cadherin [56, 62]. These processes decrease the abundance of VE-cadherin 
on the endothelial cell surface, leading to increased vascular leakage. 
 
1.4.2 Tight junctions 
Tight junctions play an essential role in regulating paracellular permeability and 
maintaining cell polarity. Downregulation of claudins, occludin and ZO-1 has been 
correlated with BBB and BRB dysfunction in various pathophysiological conditions 
such as stroke, diabetes, inflammation and brain tumors [63-65]. Phosphorylation 
and redistribution of tight junction proteins away from the cell border are induced 
by inflammatory or angiogenic mediators (e.g. hypoxia, MCP-1, VEGF or 
histamine), leading to the impairment of endothelial barrier function [65]. 
Furthermore, inflammation-induced apical redistribution of JAM-A and upregulation 
of JAM-C expression exert opposing effects on the modulation of endothelial 
permeability [66, 67]. JAM-A, which is highly expressed in the brain vascular 
system, acts as a gatekeeper to decrease permeability in endothelium [68]. On the 
contrary, JAM-C, highly expressed in lymph nodes, enhances permeability by 
regulating endothelial contraction and VE-cadherin-mediated adhesion [52, 67]. 
 
1.4.3 Endothelial cell contraction 
Endothelial cell contraction is a critical mechanism for the disruption of cell-cell 
adhesion, leading to the gap formation and increased endothelial permeability [69]. 
It is well-known that myosin light chain (MLC) phosphorylation contributes to 
actomyosin contractility and endothelial cell contraction [70, 71]. Phosphorylation 
of MLC is induced by Ca2+/calmodulin-dependent activation of MLC kinase 
(MLCK), as well as the inhibition of MLC phosphatase (MLCP) activity mediated by 
RhoA and Rho kinase (ROCK) activity [72-74]. For instance, thrombin-induced 
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endothelial permeability partially attributes to endothelial cell contraction elicited by 
an elevation of intracellular Ca2+ and activation of Rho/ROCK pathway [75]. 
 
1.5 Eph/ephrin system 
Eph receptors are named after a cell line in which the first member was discovered: 
erythropoietin-producing human hepatocellular carcinoma cell line [76]. Eph and 
the corresponding ligands ephrin (Eph family receptor in
77
teracting proteins) have 
versatile functions in embryos and adults. In the central nervous system, 
Eph/ephrins have profound effects on the development of neural crest cell, 
cerebellar granule cell migration, segmentation, topographic mapping, axon 
guidance and dendritic spine formation in embryonic development [ ]. They also 
play a role in synapse plasticity and the repair of injured nervous system in adults 
[77, 78]. Moreover, Eph/ephrins are involved in the regulation of epithelium self-
renewal, insulin secretion, bone development and remodeling, platelet aggregation 
and glomerular filtration in the kidney [79-84]. In addition, Eph/ephrins have been 
widely studied in the pathology of cancer related to tumor growth, invasiveness, 
angiogenesis and metastasis [85]. 
 
1.5.1 Eph/ephrin structure 
Eph receptors represent the largest family of receptor tyrosine kinases (RTKs), 
comprising nine EphA (EphA1-8; EphA10) and five EphB (EphB1-4, EphB6). The 
subdivision of group A and B depends on the similarities of the extracellular 
sequences and the binding affinity for corresponding ligands. Ephrin ligands 
consist of six ephrinA (ephrinA1-6) and three ephrinB (ephrinB1-3). Furthermore, 
the binding of receptor and ligand is confined in the same subclass. EphA 
receptors bind to ephrinA ligands and EphB receptors preferentially interact with 
ephrinB ligands. As an exception, ephrinA5 binds to EphB2 at high concentrations, 
and ephrinB ligands bind to EphA4 [86]. 
Eph receptors are transmembrane proteins. The extracellular part of Eph 
receptors includes an ephrin-binding domain, a cysteine-rich region, and two 
fibronectin type-III repeats. The cytoplasmic region consists of a juxtamembrane 
region, the tyrosine kinase domain, a sterile α-motif (SAM) domain and a PDZ-
binding motif. EphrinA ligands are linked to the cell membrane via a 
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glycosylphosphatidylinositol (GPI) anchor. Whereas, ephrinB ligands display an 
extracellular Eph-binding domain, a transmembrane region, a cytoplasmic tail, and 
a PDZ-binding domain [87] (Figure 3). 
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Figure 3: Structure and bidirectional signaling of Eph/ephrin. 
The structures of Eph and ephrin are illustrated (refer to the text for detailed description). The 
binding of Eph and ephrin induces forward signaling through Eph and reverse signaling via ephrin, 
namely bidirectional signaling (adapted from Salvucci O 2012). 
 
Since receptors and ligands are membrane bound proteins, cell-cell contact is 
required for inducing bidirectional signaling into the Eph-expressing cells (termed 
forward signaling) and the ephrin-expressing cells (termed reverse signaling) [88] 
(Figure 3). Eph and ephrin expressed in opposing cells interact in trans, whereas 
both expressed in the same cell result in cis interaction [89]. Moreover, once cells 
contact, clustering of the Eph/ephrin complex occurs progressively, and the 
degree of clustering determines the signal intensity and final effects. 
Tetramerization is necessary for evoking downstream signaling [90]. 
To terminate this interaction, which is required for the detachment of contacting 
cells, the Eph/ephrin complex is removed from cell surface by endocytosis into 
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Eph- or ephrin-expressing cells [89]. Intriguingly, this process is accompanied by 
the internalization of surrounding membrane compartments with other proteins. 
For instance, EphB4 stimulation results in the internalization of ephrinB2-
colocalized VEGFR2 and VEGFR3 into endothelial cells, which is essential for 
VEGF signaling [91, 92]. An alternative way to eliminate the Eph/ephrin complex is 
through proteolytic cleavage. This is accomplished by ADAM family 
metalloprotease and γ-secretase [89, 93]. This process may generate Eph/ephrin 
fragments that exert additive effects [88, 94-97]. 
 
1.5.2 Eph/ephrin signaling 
The interaction of Eph and ephrin induces forward and reverse signaling to 
modulate diverse cell behaviors such as proliferation, differentiation, adhesion and 
migration [86]. To transduce signals into cells, Eph receptors become 
tyrosine-phosphorylated and bind to PDZ domain proteins. Subsequently, several 
signal tranducers are activated: SH2 domain-containing adaptor protein 
(Grb2/7/10, Nck), Rho and Ras, focal adhesion kinase (FAK), the Jak/Stat 
pathway and the PI3K pathway [93, 98]. Although ephrinA lacks a cytoplasmic tail, 
these ligands are capable of triggering downstream signaling through several 
effectors, such as Src family kinases, ERK, Rac1, and AKT [81, 99-102]. 
Downstream signals of ephrinB are transmitted through it interacting with a variety 
of proteins which mediate SH2/PDZ-dependent and -independent signaling 
pathways [102]. Some of these signals require ephrinB phosphorylation. 
Phosphorylation of ephrinB is caused by EphB receptor engagement, activation of 
growth factor receptors (e.g. FGFR, PDGFR, Tie2) or cell membrane proteins (e.g. 
claudins) [102]. EphB-induced Src family kinases activity is responsible for ephrinB 
phosphorylation, and delayed recruitment of tyrosine phosphatase PTP-BL results 
in the dephosphorylation of ephrinB [103]. Phosphorylated ephrinB1 binds to 
SH2/SH3 domain adaptor proteins such as Grb4 [104] and STAT3 [105, 106]. 
Moreover, ephrinB interacts with PDZ motif-containing proteins, including PDZ-
RGS3 [107], GRIP [108] and syntenin-1 [109]. In addition, ephrinB interacts with 
some proteins independent of PDZ and SH2 domains, such as Par-6 [110], 
Connexin 43 [111], Dishevelled (Dsh) [112, 113], as well as Zinc-finger and 
homeodomain protein 2 (ZHX2) [114]. Furthermore, ephrinB reverse signaling has 
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been reported to activate Src-, PI3K-, JNK- and ROCK-dependent signaling 
pathways [115-117]. 
 
1.5.3 EphB/ephrinB in the vascular system 
EphB4 and ephinB2 play a prominent role in embryonic development of the 
cardiovascular system. Endothelial ephrinB2 and EphB4 are identified as markers 
for arteries and veins, respectively. EphrinB2 deficiency in mice leads to prenatal 
death caused by defects in angiogenesis and capillary network formation, as well 
as impairments in myocardial trabeculation [118]. EphB4-null mice display the 
similar phenotype, indicating that EphB4 is the prominent receptor for ephrinB2, 
and also both forward and reverse signaling are required for vascular development 
[119]. Moreover, endothelial cell specific ephrinB2 knockout mice exhibit similar 
defects as ephrinB2-deficient mice [120]. Interestingly, overexpression of ephrinB2 
in the endothelium leads to embryonic death caused by severe vascular 
impairments, such as reduced blood vessel network with thin endothelial 
connections [91]. Therefore, it reveals that the optimal ephrinB2 expression level 
in the endothelium is crucial for vascular development. Not only does endothelial 
ephrinB2 play a predominant role, ephrinB2 in mural cells is critical for their 
migration, spreading, and adhesion during vessel maturity. Targeted ablation of 
ephrinB2 in mural cells leads to perinatal lethality caused by abnormal migration of 
SMCs to lymphatic capillaries, defects of microvascular architecture and tissue 
edema [121]. Moreover, EphB2 is expressed in mesenchymal cells and binds to 
endothelial ephrinBs, while EphB3 is expressed in veins and some arteries and 
binds to mesenchymal ephrinB2. Double mutants of EphB2 and EphB3 exhibit 
various abnormalities of vascular development. This suggests that EphB and 
ephrinB interactions between endothelial cells and mesenchymal cells are critical 
for vascular network formation [122]. 
In adults, EphB and ephrinB are involved in physiological and pathological 
angiogenesis, such as wound repair, tumor angiogenesis and intraocular 
neovascularization [87, 123]. The phosphorylation of ephrinB acts as a marker for 
angiogenic vessels in neovascularization [105]. Moreover, endothelial ephrinB2 
expression is increased in remodeling arterioles undergoing arteriogenesis, which 
functions in limiting SMC migration to stabilize the vasculature [124]. Of note, 
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ephrinB reverse signaling negatively regulates blood pressure and SMC 
contractility via reduced RhoA activity, supported by the evidence that EphB6 
knockout mice and SMC specific ephrinB1 knockout mice exhibit higher blood 
pressure [125, 126]. 
 
1.5.4 EphB/ephrinB in immunity and inflammation 
The EphB/ephrinB system has been reported to regulate immune cell 
development and function. This has been widely studied in T cells. EphB6 appears 
to be essential to modulate T cell function, supported by the evidence that EphB6 
knockout mice exhibit impaired T cell responses such as defective proliferation 
and reduced cytokine release [127]. EphrinBs have been identified as dose-
dependent co-regulators together with CD3 on T cell activation. Low 
concentrations of ephrinB1 and ephrinB2 act as co-stimulators on T cell 
proliferation and downstream signaling, but switch to inhibitors on high 
concentrations [128, 129]. Moreover, double null mutant mice of ephrinB1 and 
ephrinB2 in T cells not only display reduced spleen and thymus size, weight and 
cellularity, but also show impaired T cell functions such as defective differentiation 
into Th1 and Th17 cells, reduced immune responses to infection and diminished 
IL-6 signaling [130]. Whereas, single deletion of ephrinB1 or ephrinB2 in T cells 
elicits minor effects [131, 132]. This suggests a heavy redundancy among ephrin 
family members to compensate for the deficiency. 
There is accumulating evidence showing that EphB/ephrinB expression is 
upregulated in various cell types in inflammatory diseases. For instance, the 
expression of ephrinB1 and EphB2 is strongly increased in leukocytes and 
endothelial cells in human abdominal aortic aneurysm and carotid atherosclerotic 
plaques [133, 134]. EphrinB1 expression is significantly increased in synovial 
fibroblasts and lymphocytes in rheumatoid arthritis [135]. EphrinB2 is most 
abundantly expressed in endothelial cells at atherosclerosis predilection sites [136] 
Furthermore, EphB/ephrinB contributes to the progression of inflammation through 
inducing pro-inflammatory cytokine release and regulating leukocyte chemotaxis. 
EphrinB1 stimulation enhances the secretion of TNFα in leukocytes and IL-6 in 
synovial cells [135]. EphB1 elicits the expression of MCP-1 in epithelial cells [137, 
138]. Additionally, ephrinB2 stimulates the expression of MCP-1 and IL-8 in 
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monocytes [136]. With respect to EphB/ephrinB-mediated regulation of leukocyte 
chemotaxis, the effects are still in controversy. EphrinB2 expressed in endothelial 
cells facilitates MCP-1-stimulated monocyte transmigration [124, 139]. 
Pretreatment of leukocytes with ephrinB1 effectively promotes their 
SDF-1α-dependent migration [135]. On the contrary, precoating ephrinB1, 
ephrinB2 or EphB2 on the membrane of transwell inhibits basal and chemokine-
induced leukocyte migration [133, 134, 140]. 
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1.6 Aims 
Although the EphB/ephrinB system has been extensively studied during early 
embryonic development, its function in the adult vasculature is largely unknown. 
EphrinB2 is apically expressed on quiescent endothelial cells, and the level of its 
expression depends on local microenvironmental cues such as hypoxia, contact 
with SMCs and pro-angiogenic stimulation by VEGF [141]. On the other hand, 
EphB2 is expressed on the surface of monocytes. [139] The pattern of 
EphB2/ephrinB2 expression led to the hypothesis that their interaction might be 
involved in circulating monocyte adhesion to and transmigration through the 
endothelial cell monolayer, which are pivotal processes during inflammation. 
In Part 1, the aim was to study ephrinB2 expression in endothelial cells during 
inflammation, followed by clarifying the role of endothelial cell ephrinB2 in 
monocyte diapedesis and the underlying mechanisms.  
Considering the unique feature of bidirectional signaling in the Eph/ephrin system, 
as well as the evidence that EphB2 forward signaling activates monocytes [136], it 
intrigued us to investigate the impact of ephrinB reverse signaling on the pro-
inflammatory differentiation of endothelial cells and monocyte adhesion in Part 2. 
In Part 3, to further explore the role of endothelial ephrinB2 in inflammation in vivo, 
tamoxifen inducible endothelial cell specific ephrinB2 knockout mice were 
generated. Three distinct inflammatory models (ear edema, peritonitis and 
atherosclerosis) and an arteriogenesis model were used to investigate monocyte 
extravasation and pathological progression. 
Based on the fact of heavy redundancy of ephrinB family members, the aim in Part 
4 was to distinguish which ligand (ephrinB1 and/or ephrinB2) is responsible for the 
observed pro-inflammatory differentiation of endothelial cells induced by EphB2 
stimulation. 
In Part 5, the aim was to assess the impact of endothelial ephrinB1 during 
inflammation. The expression of endothelial cell ephrinB1 under inflammatory 
conditions and its effect on monocyte diapedesis were analyzed. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
Chemicals were purchased from the following manufacturers: Roth, Merck and 
Sigma Aldrich. 
2.1.2 Reagents and kits 
2.1.2.1 Cell culture Media and supplements 
Name of the product Company 
Endothelial cell growth medium Promocell (Karlsruhe, Germany) 
Endothelial cell growth supplement 
(ECGS) 
Promocell 
RPMI1640 medium Invitrogen (Karlsruhe, Germany) 
Fetal Bovine Serum (FBS) Invitrogen 
Gelatine Sigma Aldrich (Heidelberg, Germany) 
Fibronectin BD Bioscience 
Hank’s BSS PAA (Cölbe, Germany) 
Opti-MEM® reduced serum medium Invitrogen 
Streptomycin Invitrogen 
Penicillin Invitrogen 
Fungizone® antimycotic Invitrogen 
Trypsin Invitrogen 
Trypan blue Sigma Aldrich 
MCDB-131 medium Invitrogen 
Endothelial cell growth supplement 
(ECGS) 
Sigma Aldrich 
Heparin salt Sigma Aldrich 
Sodium bicarbonate Sigma Aldrich 
L-glutamine solution Invitrogen 
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2.1.2.2 Reagents 
Name of the product Company 
MATra-A Reagent IBA (Göttingen, Germany) 
ABTS tablets Roche (Mannheim, Germany) 
SP600125 Biomol (Hamburg, Germany). 
PP2 Sigma Aldrich 
Sudan III Merk (Darmstadt, Germany) 
Expand Long Template PCR System Roche (Mannheim, Germany) 
Protein A/G PLUS-agarose Santa Cruz (Heidelberg, Germany) 
Protein A magnetic bead New England Biolabs (Frankfurt, 
Germany) 
Nitrocellulose membrane GE Healthcare (Hamburg, Germany) 
ECL Plus Western Blotting Detection 
reagent 
Millipore (Schwalbach, Germany) 
Precision Plus ProteinTM standards Biorad (Munich, Germany) 
RNAlater RNA stabilization reagent Qiagen (Düsseldorf, Germany) 
Taq Polymerase Bioron (Ludwigshafen, Germany) 
DNA standards-O’GeneRulerTM DNA 
Ladder 
Fermentas (St.Leon-Rot, Germany) 
DAPI Invitrogen 
TSATM-Cy3 system Perkin Elmer (Rodgau Jügesheim, 
Germany) 
EnvisionTM labeled polymer-HRP anti-
rabbit 
DAKO (Hamburg, Germany) 
ProLong Invitrogen 
Paraffin Sigma Aldrich 
TPA (12-O-Tetradecanoylphorbol-13-
Acetate) 
Sigma Aldrich 
Thioglycollate broth Sigma Aldrich 
Tamoxifen Sigma Aldrich 
Fluorescence-labeled dextrans Invitrogen & Sigma Aldrich 
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2.1.2.3 Kits 
Name of the product Company 
Active SHP2 DuoSet IC kit R&D 
Strata Prep PCR purification kit Agilent Technologies (Waldbronn, Germany) 
QIAprep spin miniprep kit  Qiagen 
Maxi prep plasmid kit Macherey-Nagel (Düren, Germany) 
pcDNA TM 3.1 Directional TOPO 
kit 
Invitrogen 
Competent E.coli Invitrogen 
QuantiTect SYBR Green® kit  Qiagen 
Rneasy Mini kit  Qiagen 
peqGOLD RNA kit PEQlab (Erlangen, Germany) 
Omniscript RT kit Qiagen 
 
2.1.3 Small interfering RNAs 
siRNA Target sequence Source 
si RNA ephrinB2 
 
ephrinB2siRNA2GGACUGGUACUAUACCCA
C[dT][dT] 
ephrinB2siRNA2_asGUGGGUAUAGUACCA
GUCC[dT][dT] 
ephrinB2siRNA1GGAAUAAAGAUCCAACAA
G[dT][dT] 
ephrinB2siRNA1_asCUUGUUGGAUCUUUA
UUCC[dT][dT] 
 
Sigma Aldrich 
si RNA ephrinB1  
 
N/A Qiagen 
negative control N/A Qiagen 
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2.1.4 Primers 
RT-PCR 
human RPL32 forward 5´-GTT-CATCCGGCACCAGTCAG-3´ 
human RPL32 reverse 5´-ACGTGCACATGAGCTGCCTAC-3´ 
human ephrinB1 forward 5´-GGAGGCAGACAACACTGTCA-3´ 
human ephrinB1 reverse 5´-GAACAATGCCACCTTGGAGT-3´ 
human ephrinB2 forward 5´-GAAAATACCCCTCTCCTCAACT-3´ 
human ephrinB2 reverse 5´-CTTCGGAACCGAGGATGTTGTTC-3´ 
human E-selectin forward 5´-TTCGCCTGTCCTGAAGGATG-3´ 
human E-selectin reverse 5´-TCAGTTGAAGGCCGTCCTTG-3´ 
human GM-CSF forward 5´-TCCTGAACCTGAGTAGAGAC-3´ 
human GM-CSF reverse 5´-CAAAGGGGATGACAAGCAGA-3´ 
 
Real time PCR 
mouse RPL32 forward 5´-GGGAGCAACAAGAAAACCAA-3´ 
mouse RPL32 reverse 5´-ATTGTGGACCAGGAACTTGC-3´ 
mpuse ephrinB1 forward 5´-GTAGGCCAGGGCTATTTCTG-3´ 
mouse ephrinB1 reverse 5´-TGTCTCATGAGGGTCCAAAA-3´ 
mouse ephrinB2 forward 5´-CTTTGGAGGGCCTGGATAAC-3´ 
mouse ephrinB2 reverse 5´-TCTTCATGGCTCTTGTCTGG-3´ 
human RPL32 forward 5´-AGGCATTGACAACAGGGTTC-3´ 
human RPL32 reverse 5´-GTTGCACATCAGCAGCACTT-3´ 
human E-selectin forward 5´-AGGTGAACCCAACAATAGGC-3´ 
human E-selectin reverse 5´-GCTGCACCTCTCATCATTCC-3´ 
human VCAM-1 forward 5´-CATGGAATTCGAACCCAAACA-3´ 
human VCAM-1 reverse 5´-GACCAAGACGGTTGTATCTCTGG-3´ 
 
2.1.5 Buffers and solutions 
1.0 % (w/v) Bacto-tryptone 
Luria-Bertani (LB) Medium: 
0.5 % (w/v) Yeast extracts 
1.0 % (w/v) NaCl 
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1.5 % (w/v) Agar in LB medium with 50 μg/ml ampicillin 
LB-Agar Plates: 
 
154 mM NaCl 
Ringer’s solution 
5.6 mM KCl 
2.4 mM CaCl2 
6 mM NaHCO3 
5.6 mM Dextrose 
30 mg/l Nitroplessid 
27 mg/l Adenosin 
 
0.1 M Tris HCl, pH 7.4 
Zinc fixation 
3.2 mM Ca(CH3COO)2(H2O) 
22.8 mM Zn(O2CCH3)2(H2O)2 
35.9 mM ZnCl2 
 
0.25 % Casein 
Casein blocking serum 
0.1 % BSA 
15 mM NaN3 
50 mM Tris, pH 7.6 
 
8.0 g NaCl 
Phosphate-Buffered Saline (PBS) per L 
0.2 g KCl 
1.44 g Na2HPO4 
0.2 g KH2PO4 
 
6.1 g Tris (0.5 M) 
Tris-Buffered Saline (TBS) per L 
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8.75 g NaCl (1.5 M) 
 
0.5 ml Tween were add to PBS or TBS 
0.05% PBST or TBST 
 
150 mM NaCl, 
Lysis Buffer for Western blot 
10 mM Tris, PH 7.4 
1 % Triton 
0.1 M DTT 
1 mg/ml Pepstatin A 
1 mg/ml Leupeptin  
40 mg/ml Pefa-block 
 
25.0 mM Tris 
Tris-glycine-SDS Running Buffer 
192.0 mM Glycine 
0.1 % SDS 
 
25.0 mM Tris 
Transfer Buffer 
192.0 mM Glycine 
20 % Methanol 
 
5 % milk powder in PBST 
Blocking Buffer 
 
0.2 M NaOH 
Stripping Buffer 
 
450 mM Tris 
5X (Tris-borate-EDTA) TBE buffer 
450 mM Boric acid 
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20 mM EDTA, pH 8.0 
 
10 mM Tris/HCl, pH 7.5 
6X Glycerol loading buffer 
10 mM EDTA, pH 8.0 
30 % Glycerol 
0.01 % Bromophenol blue 
0.01 % Xylene green 
 
1 % Glutaraldehyde 
Isotonic GA/PFA 
0.3 % Paraformaldehyde 
0.07 M Sodium cacodylate buffer 
 
2.1.6 Antibodies 
2.1.6.1 Secondary antibodies 
Secondary antibody Use Source 
cy2 conjugated donkey anti-
mouse IgG (H+L) 
ICC Jackson laboratories via 
Dianova (Hamburg,Germany) 
cy2 conjugated donkey anti-goat 
IgG (H+L) 
ICC Jackson laboratories via 
Dianova 
cy2 conjugated donkey anti-rat 
IgG (H+L) 
IHC/ICC Jackson laboratories via 
Dianova 
Rabbit anti-goat Immunoglobulins IHC/ICC Z0454, DAKO 
Goat anti-rabbit IgG peroxidase WB A6154, Sigma Aldrich 
Goat anti-mouse IgG peroxidase WB A4416, Sigma Aldrich 
Rabbit anti-goat IgG peroxidase WB A5420, Sigma Aldrich 
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2.1.6.2 Primary antibodies 
WB: Western blot, ICC: Immunocytochemistry, IHC: Immunohistochemistry 
Primary antibody Use Source 
Rabbit polyclonal anti-phospho-Src 
(Y419) 
WB AF2685, R&D 
(Wiesbaden, Germany) 
Rabbit polyclonal anti-phospho-PECAM-1 
(tyr713) 
WB A0547, Assaybiotech 
(Herford, Germany) 
Rabbit monoclonal anti-Src (36D10) WB 2109, Cell Signaling 
(Frankfurt, Germany) 
Goat polyclonal anti-ephrinB1 WB/IHC AF473, R&D 
Goat polyclonal anti-ephrinB2 WB/IHC AF496, R&D 
Goat polyclonal anti-VE-cadherin (C19) WB sc6458, Santa Cruz 
Mouse monoclonal anti-E-selectin IHC sc71017, Santa Cruz 
Mouse monoclonal anti-VE-cadherin WB MAB1989, Millipore 
(Schwalbach, Germany) 
Goat polyclonal anti-EphB2 WB/IHC AF467, R&D 
Mouse monoclonal anti-β-actin (AC-15) WB 6276, Abcam 
(Cambridge, UK) 
Goat polyclonal anti-CD31 (M20) WB sc1506, Santa Cruz 
Rat monoclonal anti-CD31 (MEC 13.3) IHC sc18916, Santa Cruz 
Mouse monoclonal anti-VE cadherin 
(BV6) 
ICC MAB1987, Millipore 
Rat monoclonal anti-F4/80 IHC T2006, Dianova 
(Hamburg, Germany) 
Rat anti-Mac-3 IHC 550292, BD pharmingen 
(Heidelberg, Germany) 
Mouse monoclonal anti-human PECAM-1 
(JC70A) 
ICC M0832, DAKO 
HRP-Rabbit anti-human vWF ELISA P0026, DAKO 
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2.1.7 Recombinant proteins 
Recombinant protein Dosage Source 
Human IgG1 Fc MAb  
(Clone 97924) 
1 μg/ml MAB110, R&D 
Recombinant human monocyte 
chemoattractant protein-1 
(MCP-1) 
30 ng/ml 279-MC-010, R&D 
Recombinant mouse monocyte 
chemoattractant protein-1 
(MCP-1) 
2 ng/ml 479-JE-010, R&D 
Recombinant human TNFα 1000 U/ml 210-TA-010, R&D 
Recombinant mouse TNFα 2 ng/ml GWB-47E270, Geneway Biotech 
(San Diego, USA) 
Recombinant mouse EphB2/Fc 2 μg/ml 467-B2-200, R&D 
 
 
2.1.8 Consumables 
Tissue culture plates were purchased from Greiner or TPP. Test tubes were 
obtained from Sarstedt. Transmigration transwells and compatible plates were 
obtained from BD or Greiner Bio One. Cell scrapers were purchased from Sarstedt 
Inc.  
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Isolation and culture of human umbilical vein endothelial cells 
(HUVECs) 
Human umbilical vein endothelial cells were isolated from umbilical cords 
according to the approval #336/2005 by the local ethics committee. Blood in the 
umbilical veins was flushed out with 20 ml Hank’s buffer. The veins were filled with 
dispase solution (3.1 g/l) and incubated for 30 minutes at 37°C. The solution 
together with flushed Hank’s solution was centrifuged at 1000 rpm for 5 min, and 
the pellet was re-suspended in endothelial cell growth medium containing 
supplements, 5 % FBS, 50 U/ml penicillin, 50 μg/ml streptomycin and 0.25 μg/ml 
Fungizone® antimycotic. The cells were cultured on standard plates pre-coated 
with 2 % (w/v) gelatine. 
 
2.2.1.2 siRNA transfection in HUVECs 
To transfect one well of a 6-well plate, the transfection complex was made with 3 
μg of siRNA and 3 μl of MATra-si reagent in Opti-MEM® medium to a final volume 
of 200 μl, then mixed thoroughly and incubated for 20 minutes at room 
temperature. The siRNA complex was added dropwise to the cells. Then the plate 
was placed on a magnetic plate (Universal Magnet Plate, IBA) for 20 minutes in 
the incubator allowing the beads to penetrate into the cells. For ephrinB1, efficient 
knockdown was achieved after 48 hours. However, for sufficient deletion of 
ephrinB2, cells were subjected to a second transfection after 24 hours (Figure 4). 
 
2.2.1.3 Stimulation of endothelial cells 
Endothelial cells were treated with either clustered EphB2 recombinant protein or 
EphB2-overexpressing mouse myeloma cells. Clustered EphB2 recombinant 
protein was produced by incubating 2 μg/ml EphB2/Fc and 1 μg/ml anti-IgG Fc 
antibody for 1 hour at room temperature. 7×106/ml mock-transfected and EphB2-
overexpressing mouse myeloma cells were administered to the HUVECs on one 
well of a 6-well plate. In addition, JNK inhibitor, SP600125 (20 μM), and inhibitor of 
Src family kinases, PP2 (10 μM), were applied 1 hour before exposing HUVECs 
either EphB2/Fc or EphB2-overexpressing mouse myeloma cells. 
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Figure 4: Silencing of ephrinB1 and ephrinB2 mRNA expression in HUVECs. 
HUVECs were treated with control siRNA or ephrinB2-specific siRNA or ephrinB1-specific siRNA 
by magnet-induced transfection. Knockdown efficiency was assessed by PCR (A, C) and Western 
blot (B, D). 
 
2.2.1.4 Culture of mouse myeloma cells 
The mouse myeloma cells P3XTB.A7 were cultured in suspension in RPMI1640 
medium, supplemented with 10 % FBS, 50 U/ml penicillin, 50 μg/ml streptomycin 
and 0.25 μg/ml Fungizone® antimycotic. 
 
2.2.1.5 Generation of EphB2-overexpressing mouse myeloma cells 
To get human EphB2 sequence (length 2961bp, Pubmed: 017449), monocyte 
cDNA template, a pair of designed primer and expand long template PCR system 
were applied for PCR as follows: 
 
Primer Amplification 
Number of 
Cycles 
Forward: 
CACCATGGCTCTGCGGAGGCTGGGG
GC 
Reverse: 
TCAAACCTCCACAGACTGAATCTGGTT
CATCTGCG 
95°C 30 seconds 
58°C 30 seconds 
72°C 3 minutes 
 
32 
 
                                                                                            Materials and methods 
 
34 
 
DNA product was purified with the StrataPrep PCR purification kit. Subsequently, 
the concentration and purity of the EphB2 product were determined by using the 
NanoDrop ND-1000 spectrophotometer and the absorption of sample A260/280 
would be 1.8-2.0. TOPO cloning reaction was carried out using the pcDNA TM 3.1 
Directional TOPO kit. DNA was transformed into competent E. coli. Eight clones 
were selected and cultured in LB medium containing 50 μg/ml ampicillin overnight 
individually. Bacterial stock (100 μl H2O, 100 μl glycerol, 800 μl bacteria) was 
made. Meanwhile, the construct was extracted by the QIAprep Spin Miniprep kit 
and analyzed by sequencing. The bacterial stock with correct EphB2 sequence 
was re-cultured. The plasmid was then extracted and purified by the Maxi Plasmid 
Purification kit, and eventually eluted with sterile RNase-free water. For the mock, 
the TOPO cloning reaction without DNA product was performed as described 
above. 
Mouse myeloma cells were transiently transfected with mock or EphB2 plasmid by 
polyethylenimine (PEI). 1.5×106/ml cells were seeded in one well of a 6-well plate 
in RPMI 1640 medium containing 10 % FBS without antibiotics. 2.5 μg plasmid 
was incubated with 10 μg PEI in 50 μl Opti-MEM® medium for 15 minutes at room 
temperature. The mixture was added dropwise to the myeloma cells followed by 6 
hours incubation. The transfection process was terminated by adding 2.5 ml 
complete culture medium. After 48 hours, transfected myeloma cells were ready 
for stimulation of HUVECs. 
EphB2
β-actin
 
Figure 5: Generation of mock-transfected and EphB2-overexpressing mouse myeloma cells. 
Western blot and immunofluorescence were performed to analyze the expression of EphB2 in 
mock-transfected and EphB2-overexpressing mouse myeloma cells. EphB2 was abundantly 
expressed in EphB2-overexpressing cells but not in mock-transfected cells (left panel). EphB2 is 
located on the surface of these cells (green, right panel). 
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2.2.1.6 Culture of brain endothelial cells 
bEnd5 cells were cultured in MCDB-131 medium supplemented with 20 % FBS, 2 
mM L-glutamine solution, 2 mM penicillin-streptomycin solution, 0.05 mg/ml 
ECGS, 0.1 mg/ml heparin salt  and 1 g/L sodium bicarbonate. This was done by 
collaborator Dr. Kavi Devraj. 
 
2.2.2 PCR 
2.2.2.1 RNA isolation from cells and tissues 
Cells were rinsed with ice-cold PBS, and the total RNA was extracted with the 
PeqGOLD total RNA kit according to the manufacturer’s instructions. Tissues were 
homogenized by sonification in the lysis buffer and RNA was extracted using the 
RNeasy kit. Finally, RNA was eluted with 30-50 μl RNase-free H2O and the 
concentration was measured by using the NanoDrop ND-1000 spectrophotometer. 
 
2.2.2.2 Reverse transcription 
Reverse transcription of 500 ng RNA to cDNA was performed by using the 
Omniscript RT kit according to the manufacturer´s instructions, and the mixture 
was incubated at 37°C for 1 hour. 
 
2.2.2.3 Polymerase chain reaction (PCR) 
The semi-quantification PCR was performed with 5 μl cDNA (5 μg/μl), 1 μl forward 
primer (20 μM), 1 μl reverse primer (20 μM), 0.75 μl MgCl2, 1.5 μl dNTP, 5 μl 10× 
buffer and 35.5 μl H2O to a total volume of 50 μl. PCR amplification was made in 
an automatic thermocycler (Biometra) using the following programs. 
 
step temperature time 
Pre-denaturation 95°C 5 minutes 
Denaturation 
Annealing 
Synthesis 
95°C 
55-60°C 
72°C 
30 seconds 
30 seconds 
1 minutes 
Extension 72°C 5-10 minutes 
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2.2.2.4 Agarose gel electrophoresis 
Agarose gel was made by dissolving 1.5 g agarose in 100 ml TEB buffer, and 
added 4 μl ethidium bromide additionally. The PCR products were mixed with 6x 
loading buffer. Electrophoresis was performed at 130 V for 45 min. The DNA 
standard was used to estimate the molecular size of DNA band. The relative band 
intensity was quantified by Image J.  
 
2.2.2.5 Quantitative real time PCR 
Real time PCR was performed with LightCycler instrument (Roche Diagnostics, 
Penzberg, Germany) by using the QuantiTect SYBR Green® kit. In brief, 5 μl 
cDNA (100 ng/μl), 1 μl forward primer (20 μM), 1 μl reverse primer (20 μM), 3 μl 
RNase free H2O, and 10 μl SYBR Green were added together to a final volume of 
20 μl. 
 
2.2.3 Immunohistochemistry and immunocytochemistry 
2.2.3.1 Tissue preparation, embedding in paraffin and sectioning  
Mice were sacrificed by CO2 inhalation and cervical dislocation. The chest was 
opened to expose the heart. A hole was cut in the right ventricle to allow the blood 
to come out. The left ventricle was cannulated and perfused with Ringer’s solution 
and zinc fixative. 
Tissues were isolated and fixed in zinc fixative to retain their antigen and 
morphology overnight. Then they were dehydrated by passing through 70 %, 85 
%, 96 % ethanol and isopropanol. The tissues were incubated in melted paraffin at 
60°C overnight. The next day, the tissues were embedded in paraffin blocks and 
stored at room temperature. The sections of 5 μm thickness were cut by using a 
microtome and dried for 18 hours at 40°C. Then they were processed for 
immunofluorescence staining. 
 
2.2.3.2 Cell fixation 
Endothelial cells were fixed in methanol for 15 minutes at 4°C. Thereafter, sucking 
away methanol allows cells to dry. Afterwards, they were further processed for 
immunofluorescence staining. 
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2.2.3.3 Immunofluorescence staining  
Paraffin sections were rehydrated by passing through Xylol, Xylol, isopropanol, 96 
% ethanol, 85 % ethanol, 70 % ethanol and ddH2O. 
The fixed cells or rehydrated sections were blocked by using casein blocking 
buffer for 30 minutes. Then the cells or sections were incubated with primary 
antibodies diluted in blocking buffer for 18 hours at 4°C. After completing the 
washing steps, the cells or sections were incubated with appropriate secondary 
antibodies for 1 hour at room temperature. For ephrinB1 and ephrinB2 staining, 
fluorescence amplification system was used after the secondary antibody of rabbit 
anti-goat. The cells or sections were incubated with DAKO EnvsionTM Labeled 
polymer-HRP anti-rabbit for 30 minutes, followed by TSATM-Cy3 system for 20 
seconds. Afterwards, the nuclei were counterstained by DAPI (2 μg/mL, diluted in 
PBS) for 10 minutes, and the cells or sections were mounted with Mowiol. 
 
2.2.3.4 Confocal microscopy 
Confocal microscopy, IX81 microscope equipped with IX-DSU disk unit and the 
MT20 multiwavelength illumination system, was applied to analyze immunostained 
tissue sections and cells. Quantitative image analyses were made by using the 
Olympus CellR-software (Olympus, Hamburg, Germany) or Image J (NIH, USA).  
 
2.2.4 Protein biochemistry 
2.2.4.1 Isolation of cellular protein 
The cells were rinsed once by ice-cold PBS. Lysis buffer was added onto the cells 
and incubated for 25 minutes on ice. Afterwards, the lysate was centrifuged at 
15000 rpm for 3 minutes at 4°C, and the supernatant was collected in a fresh tube. 
 
2.2.4.2 Co-immunoprecipitation 
To precipitate ephrinB2, EphB4-Fc (4 μg/ml) was added to the cell lysate and 
incubated for 2 hours at room temperature in the rolling machine. Protein A 
magnetic beads were washed by PBS (pH 7.4) and combined with the mixture to 
incubate for 2 hours. EphrinB1 was precipitated by utilizing an anti-ephrinB1 
antibody (A20) and protein A/G agarose beads using the same procedures 
described above. Thereafter, precipitates were washed by PBS, mixed with 2× 
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loading buffer and denatured for 10 minutes at 95°C. Then the samples were 
further analyzed by SDS-PAGE and western blot. 
 
2.2.4.3 Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Protein samples were denatured by adding 4× loading buffer and heating them up 
for 5 minutes at 95°C. 10 % separating gel was prepared and overlaid after 
polymerization with 4 % stacking gel according to the following recipes. The 
protein standard was used to check the running progress and to estimate the 
molecular mass of protein bands. The denatured protein samples were loaded on 
the gels. Proteins were separated by electrophoresis in running buffer at 80 V for 
the stacking gel, and 120 V for the separating gel. 
 
 
10 % separating gel 
10 ml 
4% stacking gel 
4 ml 
ddH2O 4 ml 2.7 ml 
1.5 M Tris-Cl pH8.8 2.5 ml - 
1 M Tris-Cl pH6.8 - 0.5 ml 
10 % SDS 0.1 ml 40 μl 
10 % APS 0.1 ml 40 μl 
30 % Acrylamide 3.3 ml 0.67 ml 
TEMED 4 μl 4 μl 
 
2.2.4.4 Western Blotting 
The proteins separated by SDS polyacrylamide gel were blotted onto nitrocellulose 
membrane at 350 mA for 30 to 90 minutes, depending on the molecular weight of 
the protein of interest. Then, the membrane was immersed into blocking buffer for 
30 minutes to prevent the non-specific binding. The membrane was incubated with 
the first antibody, which was diluted in PBST, for 18 hours at 4°C. Subsequently, 
the membrane was incubated with appropriate horseradish peroxidase conjugated 
secondary antibody (1:5000 diluted in blocking buffer) for 1 hour at room 
temperature. Afterwards, the membrane was developed with LuminataTM Forte 
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western HRP substrate according to the manufacturer´s instruction. The protein 
band of interest was detected using Image Quant TM LAS 4000 mini machine (GE 
Healthcare) and final analyzed by image J software. If necessary, the blot was 
incubated in stripping buffer to remove the antibodies, thereby allowing other 
proteins to be examined in the same blot by re-probing. 
 
2.2.5 Leukocyte adhesion assay 
HUVECs were pre-treated either with anti-IgG Fc antibody as control or with pre-
clustered EphB2/Fc for 6 hours at 37°C, 5 % CO2. Afterwards, HUVECs were 
rinsed by Hank’s buffer to get rid of these stimuli, which bind to Fc receptors on 
THP-1 cells. Calcein AM labeled THP-1 cells were then added to the HUVEC 
monolayer for 2 hours. The non-adherent THP-1 cells were removed by rinsing 
with PBS. The number of adherent THP-1 cells was determined by analyzing 
images with the Image J software. 
 
2.2.6 Transendothelial migration assay 
EphrinB1 or ephrinB2 expression was silenced by magnetic transfection of siRNA 
as described before. HUVECs were then cultured in transwell inserts (8 μm pore 
size, 24-well format) for 18 hours to form a confluent monolayer. 2×105 THP-1 
cells were added in the upper chamber. The medium in the lower chamber was 
supplemented with 30 ng/ml MCP-1. After 18 hours, transmigrated THP-1 cells 
were collected from the lower chamber and counted using the hemocytometer. 
 
2.2.7 Permeability assay  
200.000/cm2 bEnd5 cells were seeded onto transwell inserts (1.0 μm pore size, 
24-well format) coated with 5 μg/cm2 fibronectin and cultured for 8 days until they 
formed a monolayer. 5 μM 3 kD TXR-,10 μM 20 kD TMR- and 10 μM 70 kD FITC-
labeled dextrans were applied to the upper chamber upon treatment of bEnd5 
cells with anti-IgG Fc antibody or pre-clustered EphB2/Fc in serum-free MCDB-
131 medium for 8 hours. Aliquots from the lower chamber and the upper chamber 
were collected after 1 hour and the amount of dextrans was measured in a 
fluorescence plate reader. Permeability was calculated as lower/upper chamber 
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fluorescence ratio. The ratio for control conditions was set to 100 %. This assay 
was done by collaborator Dr. Kavi Devraj. 
 
2.2.8 vWF on cell ELISA 
vWF deposition on endothelial cell surface was measured by an in situ cell ELISA. 
HUVECs were exposed to mock-transfected and EphB2-overexpressing mouse 
myeloma cells for 1 hour, and fixed by isotonic GA/PFA. The fixed cells were 
blocked with 0.4 % BSA in PBS for 1 hour, and incubated with HRP-rabbit anti-
human vWF antibody for 1 hour. The abundance of vWF on the endothelial cell 
surface was quantified at 405 nm through an ABTS substrate reaction. This assay 
was done by collaborator Dr. Kerstin Möller. 
 
2.2.9 SHP2 activity assay 
HUVECs were exposed to mock-transfected and EphB2-overexpressing mouse 
myeloma cells for 30 minutes. SHP2 activity was measured using active SHP2 
DuoSet IC kit according to the manufacture’s instruction. 
 
2.2.10 Animal experiments 
All animal experiments were performed with permission of the Regional Council 
Karlsruhe and conformed to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health.  
 
2.2.10.1 Culture of murine femoral artery segments 
Mice were euthanized by CO2 inhalation and cervical dislocation. Femoral artery 
segments were harvested and cultured in DMEM medium supplemented with 15 
% FBS and antibiotics. 2 ng/ml mouse TNFα was applied to the artery for 6 hours 
at 37°C, 5 % CO2. To explore ephrinB1 expression, the tissue samples were 
further processed for immunofluorescence staining. 
 
2.2.10.2 Atopic dermatitis model 
Atopic dermatitis was performed with VAFNC/NgaTnd Crj mice. The mice were 
sensitized by cutaneous topical application of 150 ml of 5 % 2,4,6-Trinitrochloro-
benzene (picryl chloride, PCl) in acetone and olive oil (95:5) to their bellies and 
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footpads. Afterwards, the mice were further challenged by cutaneous topical 
application of 150 ml 0.5 % PCl in olive oil to the back skin once a week for up to 5 
weeks. Inflamed skin samples were harvested and processed for 
immunofluorescence analyses. 
 
2.2.10.3 Generation of ephrinB2EC-iKO mice 
ephrinB2flox/flox mice were crossbred with Tie2-CreERT2 transgenic mice to 
generate Tie2-CreERT2/ephrinB2flox/flox mice. These mice were received 
intraperitoneal injection of tamoxifen in Miglyol at a dose of 1 mg per day for 
consecutive 5 days and then waited for 2 weeks. This induces endothelial-specific 
ablation of ephrinB2, which was termed as ephrinB2EC-iKO mice (Figure 6). For 
control, Tie2-CreERT2/ephrinB2flox/flox mice were received the same amount of 
Miglyol. Knockdown efficiency was assessed by ephrinB2 immunostaining in 
distinct arteries. To investigate Tie2 promoter distribution, R26R/Tie2-CreERT2 
transgenic mice were subjected to tamoxifen to induce the activity of Cre 
recombinase. Report gene LacZ expression was indicated by X-gal staining in the 
different vessels (aorta, femoral artery, auricle vessel) according to protocol. This 
staining was done by Dr. Evelyn Ernst. 
 
2.2.10.4 Generation of ephrinB2EC-iKO/ApoE-/- mice 
Tie2-CreERT2/ephrinB2flox/flox mice were crossbred with ApoE-/- mice to produce 
Tie2-CreERT2/ephrinB2flox/flox/ApoE-/- mice. Tamoxifen injection was administrated 
in 2 month-old mice as described above, namely ephrinB2EC-iKO/ApoE-/- (Figure 6). 
In addition, Miglyol was injected as control. When the mice grew up to 6 months of 
age, they were sacrificed by CO2 inhalation and then perfused with Ringer’s 
solution and zinc fixative. The aortic arch, including its main branchpoints 
(brachiocephalic trunk, left common carotid artery and left subclavian artery) was 
harvested and fixed. Atherosclerotic lesions were analyzed by Sudan III staining 
using the following procedure: H2O 1 minute: 70 % ethanol 5 minutes; Sudan III 
diluted in 70 % ethanol 30 minutes; 80 % ethanol 3 minutes; H2O 3 times. 
Moreover, these aortas were dehydrated, embedded in paraffin, and further 
processed for Mac-3 immunostaining to determine the macrophage contents in the 
plaques. 
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ephrinB2EC-iKO/ApoE-/-
 
 
Figure 6: Breeding scheme for producing inducible endothelial cell specific ephrinB2 
knockout mice. 
 
2.2.10.5 TPA-induced ear edema 
Edema was induced by topically applying 1 μg TPA (12-Otetradecanoylphorbol-
13-acetate) dissolved in 20 μl of acetone on the outer surface of one ear. The 
other ear was applied with acetone as control. After 48 hours, mice were sacrificed 
by CO2 inhalation and cervical dislocation, and then perfused with Ringer’s 
solution and zinc fixative. The ears were harvested and processed for histological 
examination. 
 
2.2.10.6 Arteriogenesis model 
Mouse hindlimb ischemia model was generated as described before [124]. Mice 
were anesthetized with isoflurane, and the femoral artery was ligated distal to the 
origin of the deep femoral artery. After 7 days, the mice were euthanized by CO2 
inhalation and cervical dislocation, and then perfused with Ringer’s solution and 
zinc fixative with colored pigment, which could not pass through the capillary 
system allowing for the morphological assessment of growing collateral arterioles. 
The muscles containing the ligated femoral artery and corresponding collateral 
arterioles were harvested and further processed for histological examination. 
Colored pigment: 
8 g HKS® Designers' Gouache (Schmincke) dissolved in 50 ml zinc fixative.  
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2.2.10.7 Thioglycollate peritonitis model 
Mice were injected intraperitoneally with 1 ml of 4 % thioglycollate broth, and 
euthanized by CO2 inhalation and cervical dislocation after 6 hours. Peritoneal 
exudate cells were collected by performing lavage with 5 ml of PBS. The total cell 
number was estimated by cell counter (Millipore). Macrophages were identified by 
using Mac-3 staining. Peritoneal tissues were harvested to determine the number 
of accumulated macrophages by histological examinationd. 
 
2.2.11 Statistical analysis 
All results are expressed as means ± SD. Differences between 2 matched 
experimental groups were analyzed by unpaired Student’s t-test (InStat 3.0; 
GraphPad, USA), with a probability value of p<0.05 considered statistically significant. 
Differences among 3 or more experimental groups were analyzed by one-way 
ANOVA followed by a Bonferroni post hoc test for selected pairs of groups (InStat 3.0; 
GraphPad, USA), with a probability value of p<0.05 considered statistically significant. 
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3 RESULTS 
3.1 Analysis of the role of endothelial ephrinB2 in inflammation 
3.1.1 Expression of ephrinB2 and EphB2 in inflamed skin 
To investigate the impact of endothelial ephrinB2 on inflammation, the localization 
and expression of ephrinB2 and its receptor EphB2 were assessed in a mouse 
model of atopic dermatitis. Angiogenesis, as a hallmark of inflammation, leads to 
expanding blood flow in inflamed tissue and further leukocyte transmigration [142]. 
Immunofluorescence analyses of samples from inflamed mouse skin revealed an 
increase in the number of PECAM-1-positive capillaries indicating the occurrence 
of angiogenesis (Figure 7A, C and D). The percentage of ephrinB2/PECAM-1 
double-positive capillaries increased significantly during inflammation (Figure 7B, 
E and F). Additionally, subpopulations of F4/80-positive macrophages in the 
inflamed tissue expressed the receptor EphB2 on the cell surface (Figure 7G-L).  
 
3.1.2 Effect of endothelial ephrinB2 on monocyte diapedesis and underlying 
mechanisms 
3.1.2.1 Impact of endothelial ephrinB2 on THP-1 cell diapedesis 
To analyze the impact of endothelial ephrinB2 on monocyte diapedesis, HUVECs 
which had been pre-treated with siRNA to knockdown baseline expression of 
ephrinB2, were seeded on a transwell insert to form a monolayer. THP-1 cells, a 
monocytic cell line abundantly expressing EphB2 [139], were seeded on top of the 
HUVEC monolayer. MCP-1 was added to the lower chamber to induce 
transmigration of the THP-1 cells. The number of transmigrated THP-1 cells in the 
lower chamber was counted. Silencing of ephrinB2 expression attenuated basal as 
well as MCP-1-induced THP-1 cell transmigration (Figure. 8). 
 
3.1.2.2 Partial colocalization of ephrinB2 and PECAM-1 at endothelial cell-
cell contacts 
To elucidate the distribution of ephrinB2 in the HUVEC monolayer, 
immunofluorescence staining was performed and revealed that ephrinB2 was 
distributed at interendothelial cell contacts, and partially colocalized with 
PECAM-1, which is a crucial component of endothelial junctions and required for 
leukocyte transmigration across the endothelial cell monolayer [143]. 
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Figure 7: EphrinB2 expression is upregulated during inflammation-associated 
angiogenesis. 
EphrinB2 (red), PECAM-1 (green), EphB2 (red) and F4/80 (green) were detected by 
immunofluorescence techniques in inflamed mouse skin. Inflammation was associated with an 
increase in the number of PECAM-1-positive capillaries as indicated by the mean fluorescence 
value (MFV) of PECAM-1 (A, **p<0.01 vs. control, n=10; compare C and D). The percentage of 
ephrinB2/PECAM-1 double-positive capillaries increased during inflammation, as PECAM-1 
staining was used to normalize the number of capillaries (B, ***p<0.001 vs. control, n=5; compare 
E and F; scale bar: 100 μm). Moreover, EphB2 receptor was detected on the surface of F4/80-
positive macrophages (G-I; scale bar: 20 μm; J-L; scale bar: 10 μm). 
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Figure 8: Loss of ephrinB2 attenuates the transmigration of THP-1 cells across an 
endothelial cell monolayer. 
The relative fold of THP-1 cells transmigrating through a HUVEC monolayer in response to MCP-1 
was decreased upon siRNA-mediated ephrinB2 knockdown in endothelial cells (***p<0.001, 
*p<0.05 vs. control siRNA + MCP-1 (set to 1), ##p<0.01 vs. control siRNA, n=6) 
 
 
 
 
ephrinB2
A
PECAM-1
B
ephrinB2/PECAM-1
C
 
Figure 9: EphrinB2 colocalizes with PECAM-1 in the endothelial cell junctions. 
Immunofluorescence staining showed partial colocalization of ephrinB2 (red) and PECAM-1 
(green) at intercellular contact sites of a confluent HUVEC monolayer (A-C; scale bar: 50 μm). 
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3.1.2.3 Analysis of the association of ephrinB2 with PECAM-1 and the 
phosphorylation of PECAM-1 upon EphB2 stimulation 
To further analyze how the association of PECAM-1 and ephrinB2 changes in 
endothelial cells upon interaction with monocytes, human EphB2-overexpressing 
mouse myeloma cells were utilized to mimic a characteristic of monocytes along 
with mock-transfected myeloma cells as negative control. HUVECs were exposed 
to these cells and subsequent pull-down experiments with cell lysates were carried 
out. This result revealed that there was little co-precipitation of ephrinB2 and 
PECAM-1 upon exposure of HUVECs to mock-transfected myeloma cells (Figure 
10A). This interaction between ephrinB2 and PECAM-1 was significantly 
enhanced when HUVECs were exposed to EphB2-overexpressing mouse 
myeloma cells (Figure 10A). Treatment of HUVECs with the same stimuli elicited 
PECAM-1 phosphorylation (Figure 10B) which is frequently associated with 
leukocyte transmigration [144, 145]. 
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Figure 10: EphB2 stimulation of HUVECs enhances the association of ephrinB2 with 
PECAM-1 and also induces PECAM-1 phosphorylation. 
Co-immunoprecipitation revealed that PECAM-1 associated with ephrinB2 in HUVECs upon 
exposure to EphB2-overexpressing mouse myeloma cells for 3 hours as compared to control (A, 
*p<0.05 vs. mock myeloma, n=5). Likewise, PECAM-1 phosphorylation was triggered by the same 
stimuli within 30 minutes (B, *p<0.05 vs. mock myeloma (set to 1), n=5). 
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Since the phosphorylation of PECAM-1 largely depends on Src family kinases 
(SFKs) [146], its inhibitor PP2 was used to clarify whether SFKs are involved in 
mediating EphB2-induced phosphorylation of PECAM-1. In fact, PP2 abrogated 
both basal and EphB2-triggered PECAM-1 phosphorylation in HUVECs (Figure 
11A). Moreover, Src activity was increased in HUVECs upon interaction with 
EphB2-overexpressing mouse myeloma cells, as evidenced by phosphorylation at 
tyrosine residue 419 (Figure 11B). In addition, a reduction of SHP2 activity was 
observed (Figure 11C). 
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Figure 11: EphB2-induced phosphorylation of PECAM-1 depends on Src family kinases. 
HUVECs were pre-treated with DMSO or PP2 (10 μM) for 1 hour before they were exposed to 
mock-transfected or EphB2-overexpressing mouse myeloma cells for 30 min. PP2 blocked both 
basal and EphB2-triggered phosphorylation of PECAM-1 as confirmed by Western blot analyses 
(A). Phosphorylation of Src Y419 was enhanced (B, ***p<0.001 vs. mock myeloma (set to 1), n=4), 
while SHP2 activity was diminished under these conditions (C, *p<0.05 vs. mock myeloma (set to 
1), n=4). 
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3.1.2.4 Analysis of the association of ephrinB2 with adherens and tight 
junction proteins upon EphB2 stimulation 
The aforementioned results reveal that ephrinB2 is located at the intercellular 
junction and associates with PECAM-1 upon EphB2 stimulation. Thus, we further 
investigated whether ephrinB2 is associated with endothelial cells adherens 
junction or tight junction proteins. Co-immunoprecipitation revealed that the 
interaction of VE-cadherin with ephrinB2 was enhanced when HUVECs were 
exposed to EphB2-overexpressing mouse myeloma cells (Figure 12A). Likewise, 
the association of ZO-1, a cytoplasmic tight junction protein, with ephrinB2 was 
strengthened as well (Figure 12B). 
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Figure 12: EphrinB2 physically interacts with adherens junction and tight junction proteins 
upon EphB2 stimulation. 
As revealed by co-immunoprecipitation techniques, physical interaction of VE-cadherin (A) or ZO-1 
(B) with ephrinB2 was enhanced upon exposure of HUVECs to EphB2-overexpressing mouse 
myeloma cells (*p<0.05, **p<0.01 vs. mock myeloma (set to 1), n=5). 
 
3.1.2.5 Assessment of the distribution of VE-cadherin upon EphB2 
stimulation 
VE-cadherin, which is required for maintaining vascular integrity, represents a 
barrier for leukocyte extravasation [53]. EphB2 stimulation induced partial 
displacement of VE-cadherin from HUVEC junctions (Figure 13, arrow), which is 
critical for loosening cell contacts and promoting leukocyte diapedesis [36]. 
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Figure 13: Internalization of VE-cadherin is induced by EphB2 stimulation of HUVECs. 
Immunofluorescence staining of a HUVEC monolayer was performed. VE-cadherin (green) was 
displaced from interendothelial cell junctions upon EphB2/Fc stimulation for 30 minutes (B), 
compared to anti-IgG Fc treatment as control (A, arrow; scale bar: 50 μm). 
 
Taken together, the aforementioned results suggest that the expression of 
endothelial ephrinB2 increases in the capillaries of the inflamed tissue. EphrinB2 
promotes monocyte diapedesis, probably due to EphB2-induced Src activity, 
PECAM-1 phosphorylation and VE-cadherin internalization in endothelial cells. 
 
3.2  Examination of the impact of ephrinB reverse signaling on the pro-
inflammatory responses of endothelial cells 
Leukocyte adhesion is an initial process for leukocyte extravasation, including 
leukocyte rolling, activation and firm adhesion on the inflamed endothelial cells. 
Pro-inflammatory activation of endothelial cells, such as upregulated expression of 
adhesion molecules, plays a profound role in this process [19]. EphrinB2 has been 
reported to induce EphB2 forward signaling on monocytes and to promote the 
release of pro-inflammatory cytokines (IL-8 and MCP-1) [136]. Considering that 
the EphB/ephrinB system transduces signals in a bidirectional manner, we 
hypothesized that EphB2-stimulated reverse signaling via ephrinB ligands might 
affect the activation of endothelial cells. 
 
3.2.1 Assessment of the expression of pro-inflammatory molecules in 
endothelial cells upon EphB2 stimulation 
Exposure of HUVECs to EphB2-overexpressing mouse myeloma cells (Figure 
14A) or soluble EphB2 receptor bodies (Figure 14B-D) elicited the upregulation of 
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E-selectin expression, both on mRNA and protein level. Since ephrinB reverse 
signaling has been linked to the activation of c-Jun N-terminal kinases (JNK), 
which is a well-known determinant of E-selectin expression [115, 147], it was 
assessed whether JNK is involved in EphB2-stimulated E-selectin expression. To 
this end, JNK activity was inhibited by SP600125 prior to EphB2 stimulation and 
this blocked E-selectin expression (Figure 14E). 
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Figure 14: EphB2 stimulation triggers JNK-mediated upregulation of E-selectin expression 
in endothelial cells. 
PCR analyses revealed an increased E-selectin mRNA expression in HUVECs when exposed to 
EphB2-overexpressing mouse myeloma cells (A, *p<0.05 vs. mock myeloma (set to 1), n=8) or 
treated with pre-clustered EphB2/Fc (B, *p<0.05 vs. anti-IgG Fc control (set to 1), n=6). 
Consistently, the upregulation of E-selectin expression was detected in EphB2/Fc-stimulated 
HUVECs by immunofluorescence techniques (C and D, green; scale bar: 50 μm). Moreover, 
treatment of HUVECs with the JNK inhibitor SP600125 inhibited EphB2/Fc-induced upregulation of 
E-selectin expression (E, *p<0.05 vs. anti-IgG Fc control (set to 1), #p<0.05 vs. EphB2/Fc, n=6). 
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Furthermore, treatment with EphB2-overexpressing mouse myeloma cells elicited 
the deposition of von Willebrand factor (vWF) on the surface of endothelial cells 
(Figure 15A), which is a critical determinant of platelet adhesion and leukocyte 
extravasation [148]. Moreover, treatment with soluble EphB2 receptor bodies 
resulted in an increased expression of granulocyte/macrophage colony-stimulating 
factor (GM-CSF) (Figure 15B), which promotes monocytes differentiation into 
macrophages and subsequently activates leukocytes [149, 150]. The same stimuli 
induced the upregulation of vascular cell adhesion molecule 1 (VCAM-1) 
expression (Figure 15C), which mediates leukocyte firm adhesion. In addition, 
intercellular adhesion molecule-1 (ICAM-1) expression was not changed by 
EphB2/Fc stimulation (not shown). 
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Figure 15: EphB2 elicits GM-CSF and VCAM-1 expression and vWF release in endothelial 
cells. 
ELISA analyses were performed to determine the release of vWF on the surface of endothelial 
cells, which had been treated with EphB2-overexpressing mouse myeloma cells for 1 hour. This 
stimulation enhanced vWF release as compared with mock myeloma cells (A, *p<0.05 vs. mock 
myeloma (set to 1), n=5). As evidenced by PCR analyses, the expression of GM-CSF mRNA and 
VCAM-1 mRNA in endothelial cells was increased upon exposure to clustered EphB2/Fc for 3 
hours compared to anti-IgG Fc control (B, C, *p<0.05 vs. anti-IgG Fc control (set to 1), n=4-6). 
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3.2.2 Analysis of THP-1 cell adhesion upon EphB2 stimulation 
To further investigate the functional aspect of EphB2-activated endothelial cells, 
adhesion assays were performed. HUVECs were treated with clustered EphB2/Fc 
or anti-IgG Fc control for 6 hours, followed by the removal of these stimuli through 
rinsing HUVECs with PBS. THP-1 cells were then added on top of endothelial cells 
and allowed to adhere for 2 hours. The number of adherent THP-1 cells to 
EphB2/Fc pre-treated HUVECs was significantly enhanced (Figure 16). 
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Figure 16: EphB2 stimulation of endothelial cells increases the attachment of THP-1 cells. 
The number of fluorescent THP-1 cells (green) adhering to EphB2/Fc-prestimulated HUVECs (B; 
scale bar: 500 μm) was significantly increased as compared to anti-IgG Fc control-treated HUVECs 
(A). The number of adherent cells was counted per field using image J (C, ***p<0.001 vs. anti-IgG 
Fc control, n=3). 
 
3.2.3 Examination of the endothelial barrier function upon EphB2 stimulation 
A hallmark of inflammation is an increase in endothelial permeability, which leads 
to edema formation in inflamed tissue [48]. The aforementioned results indicate 
that EphB2 stimulation increases Src activation (Figure 11B) which is a prominent 
regulator of vascular permeability [151]. Moreover, EphB2 triggers VE-cadherin 
internalization, which leads to the disassembly of adherens junctions (Figure 13). 
Based on these findings, we next hypothesized that EphB2 stimulation may 
contribute to the disruption of the endothelial barrier function. The bEnd5 mouse 
brain endothelioma cell line, as an in vitro model for blood brain barrier (BBB) 
[152], was utilized in the permeability assay. bEnd5 cells were seeded on the 
inserts to form a monolayer and pre-treated with clustered EphB2/Fc. 3 kD TXR,  
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Figure 17: EphB2 impairs the barrier function of brain endothelial cells. 
Prolonged EphB2/Fc stimulation of bEnd5 cells for 8 hours increased endothelial permeability as 
evidenced by the higher amount of penetrating fluorescence-labeled dextrans with different 
molecular weights (3kD, 20kD and 70kD), as compared to anti-IgG Fc-treated cells (***p<0.001, 
**p<0.01 vs. anti-IgG Fc control, n=4). 
 
20 kD TMR and 70 kD FITC-labeled dextrans were administrated in the upper 
chamber. The flux of fluorescence-labeled dextrans across endothelial monolayer 
into the lower chamber was increased in EphB2/Fc-stimulated bEnd5 cells when 
compared with anti-IgG Fc antibody-treated cells (Figure 17). 
 
Collectively, these results suggest that EphB2-stimulated reverse signaling in 
endothelial cells not only upregulates the expression of pro-inflammatory 
molecules and thereby enhancing THP-1 cell attachment, but also increases 
permeability of the endothelial cell monolayer. 
 
3.3  Exploration of the effect of endothelial ephrinB2 on inflammation in vivo 
The above findings and earlier publications suggest that expression of ephrinB2 in 
endothelial cells is upregulated during inflammation and plays a vital role in 
monocyte extravasation by interacting with monocyte EphB2. To clarify the role of 
endothelial ephrinB2 in inflammatory processes, inducible endothelial cell specific 
ephrinB2 knockout mice (ephrinB2EC-iKO) were utilized to analyze monocyte 
extravasation under conditions of TPA-induced ear edema and thioglycollate-
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elicited peritonitis. Additionally, ephrinB2EC-iKO/ApoE-/- mice were generated to 
directly explore the impact of endothelial ephrinB2 on the atherosclerotic plaque 
formation. Finally, an arteriogenesis model was set up to examine the role of 
ephrinB2 in the collateral remodeling process. 
 
3.3.1 Generation of ephrinB2EC-iKO mice 
We crossbred ephrinB2flox/flox mice with Tie2-CreERT2 transgenic mice to generate 
Tie2-CreERT2 /ephrinB2flox/flox mice. Tamoxifen was injected to selectively delete 
ephrinB2 expression in endothelial cells, referred to as ephrinB2EC-iKO mice. For a 
negative control, the same amount of Miglyol, a solvent of tamoxifen, was injected. 
To explore the deletion of floxed ephrinB2 in distinct arteries, the distribution of 
Tie2 promoter was examined first. Reporter gene LacZ expression is only 
activated by Cre recombinase, whose expression is driven by the Tie2 promoter. 
Therefore, X-gal staining, which is used to indicate LacZ expression, was 
performed to determine the distribution of Tie2 promoter in distinct arteries of 
tamoxifen-treated R26R/Tie2-CreERT2 mice. It revealed that the Tie2 promoter 
was abundantly expressed in endothelial cells of the auricle vessels (Figure 18A), 
whereas it was sparsely expressed in large arteries, such as the aorta (Figure 
18B) and the femoral artery (Figure 18C). Furthermore, to assess the efficiency of 
ephrinB2 ablation, we performed immunofluorescence staining of ephrinB2 in both 
auricle and femoral arteries from control and ephrinB2EC-iKO mice. Deletion of 
ephrinB2 expression in endothelial cells was displayed in the auricle artery (Figure 
18F, D and E). However, only little deletion was detected in the femoral artery 
(Figure 18G and H). It indicated that the deletion of endothelial ephrinB2 was more 
efficient in small arteries than in conduit arteries. Therefore, knockdown efficiency 
of endothelial ephrinB2 is uneven in distinct arteries due to the asymmetrical 
distribution of Tie2 promoter. 
 
3.3.2 Analysis of TPA-induced ear edema in ephrinB2EC-iKO mice 
TPA-induced ear edema has been widely applied as a model for inflammation 
[153]. Topical application of TPA for 48 hours resulted in a remarkable increase in 
ear thickness and the number of accumulated macrophages in the epidermis and 
dermis, which were assessed by Mac-3 immunostaining (Figure 19A, B, C and E). 
However, no difference in ear edema formation and macrophage accumulation 
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could be observed when comparing TPA-treated control and ephrinB2EC-iKO mice 
(Figure 19A, B, E and F). 
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Figure 18: Examination of endothelial ephrinB2 knockdown efficiency in ephrinB2EC-iKO 
mice. 
X-gal staining was performed to examine the expression of LacZ (blue) and to indicate Tie2 
promoter expression in the sections of auricle vessels (A), the aorta (B), and the femoral artery (C) 
in tamoxifen-treated R26R/Tie2-CreERT2 mice. Immunofluorescence analysis was performed to 
detect ephrinB2 (red) in the auricle and femoral arteries from control (D, G) and ephrinB2EC-iKO (E, 
H). In the auricle artery of ephrinB2EC-iKO mice (E; scale bar: 20 μm), the ephrinB2-specific 
fluorescence intensity in endothelial cells was reduced by 80% (F, ***p<0.001 vs. control, n=5). 
However, endothelial ephrinB2 expression was not effectively ablated in the femoral artery of 
ephrinB2EC-iKO mice (H; scale bar: 50 μm), as compared to control mice (G). 
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Figure 19: Analysis of ear edema formation and macrophage accumulation induced by TPA 
in ephrinB2EC-iKO mice. 
Ear thickness was determined in cross-sections of auricles (3 to 4 independent regions per sample) 
and accumulated macrophages were indicated by Mac-3 immunostaining. Upon TPA treatment, 
ear thickness was markedly increased (A, *p<0.05 vs. control, #p<0.05 vs. ephrinB2EC-iKO control, 
n=5-6). Similarly, the number of accumulated macrophages was significantly increased as well (B, 
***p<0.001 vs. control; compare C and E; ###p<0.001 vs. ephrinB2EC-iKO control, n=5-6; compare D 
and F; scale bar: 50 μm). However, endothelial ephrinB2 deficiency did not make any difference in 
ear thickness (A) and the amount of macrophages (B, compare E and F) upon TPA-induced 
inflammation. 
 
3.3.3 Analysis of thioglycollate-elicited peritonitis in ephrinB2EC-iKO mice 
Peritonitis induced by thioglycollate is utilized to evaluate a sequential recruitment 
of leukocytes into the peritoneum, starting with an influx of neutrophils and then 
followed by monocytes [154]. Peritoneal exudate cells and inflamed tissues were 
collected 6 hours after induction of peritonitis. However, in comparison to control,  
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Figure 20: Examination of the influx of cells in lavage and macrophage accumulation in 
peritoneal tissue in the model of thioglycollate-elicited peritonitis in ephrinB2EC-iKO mice. 
Upon induction of peritonitis by intraperitoneally injecting thioglycollate, the total cell number in the 
lavage was enumerated (A, n=4-6). The percentage of Mac-3-positive cells in lavage (B, n=4-6) 
and the number Mac-3-positive cells in peritoneal tissue (C, n=7) were determined by 
immunofluorescence staining. No difference of these parameters was observed when comparing 
control and ephrinB2EC-iKOmice. 
 
no difference in the number of infiltrated cells or the percentage of Mac-3-positive 
cells in the lavage was observed in ephrinB2EC-iKO mice. Likewise, the number of 
macrophages present in peritoneal tissue was also similar in the two groups 
(Figure 20, A-C). 
 
3.3.4 Analysis of atherosclerosis in ephrinB2EC-iKO mice 
Atherosclerosis is a chronic inflammation of the arterial wall [155]. Previous 
studies indicate that ephrinB2 is most abundantly expressed in endothelial cells at 
atherosclerosis predilection sites of the mouse aorta. EphrinB2 promotes the 
adhesion and the pro-inflammatory activation of EphB receptor-expressing 
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Figure 21: Analysis of plaque formation and plaque-associated macrophage accumulation 
in ephrinB2EC-iKO/ApoE-/- mice. 
The atherosclerotic plaque was visualized by Sudan III staining, and its size was expressed as a 
percentage of the area stained with dye in the total area of aorta. Quantification of the infiltrated 
macrophages was assessed by the intensity of Mac-3 staining. There was no difference in plaque 
size (A) and the number of macrophages (B, n=6) when comparing control and 
ephrinB2EC-iKO/ApoE-/- mice. 
 
monocytes [136]. Endothelial ephrinB2 may thus contribute to the pathogenesis of 
atherosclerosis. In this context, Tie2-CreERT2/ephrinB2flox/flox/ApoE-/- mice were 
generated. In 2 month-old mice, while Miglyol was injected as a control, tamoxifen 
was administrated to delete endothelial ephrinB2 expression, referred to as 
ephrinB2EC-iKO/ApoE-/- mice. When comparing control and ephrinB2EC-iKO/ApoE-/- 
mice at 6 months of age, there was no significant difference in plaque size, 
determined by Sudan III staining. Moreover, the number of macrophages present 
in the plaques, indicated by Mac-3 staining, was also similar. 
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3.3.5 Analysis of arteriogenesis in ephrinB2EC-iKO mice 
In case of major arterial occlusion, small arterioles transform into conductance 
arteries to compensate for the lack of blood flow, a process termed arteriogenesis. 
[156]. A previous publication shows that endothelial ephrinB2 expression is 
increased in arterioles undergoing arteriogenesis, which effectively limits SMC 
migration and facilitates monocyte accumulation [124]. In this regard, we 
hypothesized that the deficiency of endothelial ephrinB2 may have an inhibitory 
impact on the progression of arteriogenesis. To verify this, arteriolar remodeling 
was induced by ligating the femoral artery for 7 days. Compared to sham, the 
diameter of collateral arteries was increased after ligation (Figure 22E, A and C). 
However, this parameter was no difference when comparing control and 
ephrinB2EC-iKO mice (Figure 22E, C and D). Moreover, macrophage accumulation 
in the perivascular space of the remodeling collateral arteries was similar in control 
and ephrinB2EC-iKO mice (Figure 22J, H and I). 
 
Taken together, four in vivo mouse models related to monocyte extravasation and 
differentiation into macrophages fail to show that endothelial ephrinB2 has an 
impact on monocyte infiltration, inflammatory pathology, and the progression of 
arteriogenesis. 
 
3.4 Assessment of the role of ephrinB1 reverse signaling in EphB2-
stimulated pro-inflammatory differentiation of endothelial cells 
Since ephrinB1 and ephrinB2 in endothelial cells bind to EphB2, we next 
elucidated which ligand is responsible for EphB2-induced pro-inflammatory 
activation of the endothelial cells. The expression of both ligands in HUVECs was 
individually silenced by siRNA pretreatment. While loss of ephrinB1 abolished 
EphB2-triggered upregulation of E-selectin expression, knockdown of ephrinB2 
had no significant effect (Figure 23A). This finding was corroborated by the fact 
that an increase of E-selectin expression induced by the stimulation with soluble 
EphB4 receptor bodies, which specifically interact with ephrinB2, was less 
effective than EphB2 stimulation (Figure 23B). 
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Figure 22: Analysis of the formation of collateral arteries in arteriogenesis in ephrinB2EC-iKO 
mice. 
Collateral arteries were visualized by pigment perfusion (A-D) and immunostaining (G-J). Diameter 
of the collateral artery was significantly increased upon arteriogenesis (E, *p<0.05 vs. sham; 
compare A and C; #p<0.05 vs. ephrinB2EC-iKO sham, n=5-6; compare B and D; arrow; scale bar: 80 
μm). However, the growth of collateral arteries was not blocked in ephrinB2EC-iKOmice as compared 
to control mice (E, compare C and D; arrow). Perivascular macrophages were determined by 
Mac-3 staining. No difference in the number of macrophages was detected (J, ***p<0.001 vs. 
sham; compare F and H; ###p<0.001 vs. ephrinB2EC-iKO sham, n=5-6; compare G and I; scale bar: 
50 μm). 
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Figure 23: EphB2-induced E-selectin upregulation is dependent on ephrinB1 reverse 
signaling. 
Knockdown of ephrinB1 expression, rather than ephrinB2, attenuated EphB2/Fc-induced 
upregulation of E-selectin mRNA expression in HUVECs (A, ***p<0.001 vs. control siRNA + anti-
IgG Fc control (set to 1), ##p<0.01 vs. control siRNA + EphB2/Fc, n=6-12). Likewise, EphB4/Fc, 
was not capable of eliciting a significant upregulation of E-selectin mRNA expression in HUVECs 
as compared to EphB2/Fc treatment (B, **p<0.01, *p<0.05 vs. anti-IgG Fc control (set to 1), 
#p<0.05 vs. EphB2/Fc, n=7). 
 
3.5 Analysis of the impact of endothelial ephrinB1 on inflammation 
There is accumulating evidence indicating that ephrinB1 is upregulated and might 
be associated with inflammatory pathogenesis by modulating cytokine release and 
leukocyte chemotaxis [133-135, 140]. Considering the aforementioned results 
suggesting that ephrinB1 reverse signaling is responsible for EphB2-induced pro-
inflammatory change of endothelial cells, it intrigued us to investigate the role of 
endothelial ephrinB1 in inflammation. 
 
3.5.1 Expression of ephrinB1 under inflammatory conditions 
We first examined the expression of endothelial ephrinB1 in inflammation using 
three different models: inflamed mouse skin model, TNFα-stimulated HUVECs and 
femoral artery segments. 
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3.5.1.1 Expression of ephrinB1 in endothelial cells of inflamed mouse skin 
Immunofluorescence analyses were performed on the inflamed mouse skin 
samples from atopic dermatitis model as described before (Figure 7). 
Inflammation-associated angiogenesis was indicated by the upregulation of 
PECAM-1-positive capillaries (Figure 24A, C and E). The percentage of 
ephrinB1/PECAM-1 double-positive capillaries markedly increased during 
inflammation (Figure 24B, D and F). 
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Figure 24: EphrinB1 expression is enhanced in angiogenic capillaries in inflamed mouse 
skin. 
PECAM-1 (green) and ephrinB1 (red) were detected by immunofluorescence staining in murine 
atopic dermatitis model. Mean fluorescence value (MFV) of PECAM-1 was increased, indicating 
that inflammation leads to angiogenesis (A, ***p<0.001 vs. control, n=10; compare C and E). The 
percentage of ephrinB1/PECAM-1 double-positive capillaries was significantly increased (B, 
**p<0.01 vs. control, n=5; compare D and F; scale bar: 100 μm). 
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3.5.1.2 Expression of ephrinB1 and ephrinB2 in endothelial cells upon pro-
inflammatory stimulation 
To analyze the abundance of ephrinB1 and ephrinB2 upon inflammatory stimuli in 
vitro, HUVECs were subjected to the pro-inflammatory cytokine, TNFα. RT-PCR 
and Western blot analyses were performed and revealed that TNFα triggered the 
upregulation of ephrinB1 expression (Figure 25A and B), but not ephrinB2 (Figure 
25C and D), in endothelial cells. 
Next, an ex vivo experiment was performed by incubating murine femoral artery 
segments with TNFα. Immunofluorescence staining was carried out and revealed 
that endothelial ephrinB1 abundance was increased upon TNFα treatment (Figure 
26A, B and C). 
 
3.5.1.3 Expression of endothelial ephrinB1 in venules in the arteriogenesis 
model 
In contrast to ephrinB2, ephrinB1 is also expressed in venous endothelial cells, 
which allows ephrinB1 to participate in monocyte extravasation. To investigate 
whether ephrinB1 expression is affected by inflammation-associated vascular 
remodeling processes, this was examined in the hindlimb ischemia model. 
Immunofluorescence staining revealed that ephrinB1 expression was significantly 
upregulated in endothelial cells of venules running in parallel to the remodeling 
collateral arterioles (Figure 27C, A and B). 
 
3.5.2 Effect of endothelial ephrinB1 on monocyte diapedesis 
Since the expression of endothelial ephrinB1 is upregulated under inflammatory 
conditions, we hypothesized that it might play a role in monocyte extravasation. 
 
3.5.2.1 Role of endothelial ephrinB1 in THP-1 cell transmigration 
To examine the impact of ephrinB1 on monocyte diapedesis, transendothelial cell 
migration assay was performed. HUVECs were pre-treated with specific siRNA to 
silence ephrinB1. While basal transmigration of THP-1 cells across the endothelial 
cell monolayer was not affected by loss of ephrinB1, MCP-1-induced 
transmigration was significantly reduced upon knockdown of ephrinB1 in 
endothelial cells (Figure 28). 
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Figure 25: TNFα elevates the expression of ephrinB1, but not ephrinB2, in HUVECs. 
Exposure of HUVECs to TNFα (1000 U/ml) increased ephrinB1 expression, assessed by RT-PCR 
(3 hours treatment; A, **p<0.01 vs. control, n=5) and Western blot analyses (B, *p<0.05 vs. 0 
hours, n=4). The abundance of ephrinB2 upon TNFα stimulation was slightly attenuated on mRNA 
level (3 hours treatment; C, **p<0.01 vs. control, n=5). No significant difference was detected on 
protein level (D, n=4). 
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Figure 26: TNFα induces upregulation of ephrinB1 expression in murine endothelial cells. 
Freshly isolated murine femoral arteries were incubated with mouse TNFα (2 ng/ml) for 6 hours. 
EphrinB1 (red) and PECAM-1 (green) were detected by immunofluorescence staining. TNFα 
treatment increased the abundance of ephrinB1 in endothelial cells (A, *p<0.05 vs. control, n=3; 
compare B and C; scale bar: 50 μm). 
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Figure 27: Endothelial ephrinB1 expression is upregulated in venules near to the 
remodeling arterioles in the arteriogenesis model. 
EphrinB1 expression (red) was assessed by immunofluorescence staining. As compared with 
sham-operated control (A), fluorescence intensity of endothelial ephrinB1 was significantly 
increased in venules, adjacent to collateral arterioles undergoing remodeling (C, *p<0.05 vs. sham, 
n=5; compare A and B; scale bar: 50 μm). 
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Figure 28: EphrinB1 supports THP-1 cell transmigration through an endothelial cell 
monolayer. 
EphrinB1 expression in endothelial cells was effectively silenced by siRNA transfection. 
MCP-1-induced transmigration of THP-1 cells was blunted in ephrinB1-deficient endothelial cells 
(***p<0.001, **p<0.01 vs. control siRNA+MCP-1 (set to 1), n=6). 
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3.5.2.2 Examination of the association of PECAM-1 and ephrinB1 upon 
EphB2 stimulation 
To elucidate the mechanism through which ephrinB1 assists monocyte 
transmigration, we hypothesized that ephrinB1 might directly interact with 
PECAM-1 in the same manner as ephrinB2. Co-immunoprecipitation was 
performed in HUVECs subjected to mock-transfected and EphB2-overexpressing 
mouse myeloma cells. However, PECAM-1 did neither co-precipitate upon 
exposure to mock nor EphB2-overexpressing mouse myeloma cells. 
 
IP: ephrinB1
Blot: PECAM-1
Blot: ephrinB1
 
Figure 29: EphrinB1 does not physically interact with PECAM-1. 
Analysis of the interaction between ephrinB1 and PECAM-1 was carried out by pulling down 
ephrinB1 (IP) with its antibody and subsequently detected PECAM-1 and ephrinB1 by western blot 
analysis. PECAM-1 did not co-precipitate with ephrinB1 even upon EphB2 stimulation. 
 
Taken together, these results indicate that endothelial ephrinB1 expression is 
upregulated during inflammation and plays a role in monocytes extravasation. 
EphrinB1 reverse signaling not only mediates EphB2 stimulated-pro-inflammatory 
molecule expression in endothelial cells, but also facilitates monocyte diapedesis. 
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4 DISCUSSION 
4.1 The role of endothelial ephrinB2 in inflammtion 
4.1.1 Endothelial ephrinB2 expression is upregulated during inflammation 
Eph receptors represent the largest family of receptor tyrosine kinases (RTKs). 
Binding to their corresponding ligand ephrins induces bidirectional signaling, by 
which Ephs and ephrins control numerous physiological and pathological functions 
[88]. In endothelial cells, an array of Eph receptors (EphA2, EphB1-B4) and 
ephrins (A1, B1, B2) are expressed [157]. Among them, ephrinB2 has been 
intensively studied in the embryonic vasculature as a marker of arterial endothelial 
cells. In the adult organism, the effect of ephrinB2 is largely unknown. In our study, 
we noted that ephrinB2 was abundantly expressed in endothelial cells during 
inflammation-related angiogenesis in the atopic dermatitis model. This is in line 
with previous findings showing that ephrinB2 expression is enhanced under 
inflammatory conditions. Highly expressed EphrinB2 has been detected in 
intestinal epithelial cells during inflammatory bowel diseases and also in 
endothelial cells at arteriosclerosis predilection sites [136, 137]. This finding 
intrigued us to further investigate the role of endothelial ephrinB2 during 
inflammation. 
EphB receptors are extensively expressed in leukocytes. For instance, 
lymphocytes express EphB1-4, B6; monocytes express EphB1-3, EphB6; and 
granualocytes express EphB1-B4 [157]. EphBs have profound effects on 
modulating immune cell development, activation and chemotaxis [130, 133, 135, 
157]. In this study, EphB2 was located on the surface of macrophages. This is in 
line with previous reports demonstrating that EphB2 expression on the surface of 
monocytes is upregulated during their differentiation into macrophages and also 
upon stimulation with PMA [134, 136]. 
 
4.1.2 Endothelial ephrinB2 facilitates monocyte transmigration 
Previous publications have indicated that ephrinB2 is located on the luminal 
surface of quiescent endothelial cells, which allows it to interact with receptors 
expressed on circulating leukocytes [141]. In this context, ephrinB2 interacts with 
EphB2-expressing monocytes and induces EphB2 forward signaling, leading to 
the release of IL-8 and MCP-1 from monocytes [136]. Thus, we hypothesized that 
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binding of endothelial cell ephrinB2 and monocyte EphB2 may affect monocyte 
extravasation during inflammation. We initially focused on understanding the role 
of ephrinB2 in monocyte transmigration through the endothelial cell monolayer 
since this process is a critical and irreversible step. Primary HUVECs were utilized 
in in vitro studies as endothelial cells in both the umbilical artery and vein 
abundantly express ephrinB2 [141]. THP-1 cells, a monocytic cell line with EphB2 
expression on the cell surface, were applied in the transendothelial cell migration 
assay [139]. The results indicated that MCP-1-induced THP-1 cell transmigration 
through the endothelial cell monolayer was blocked by loss of endothelial ephrinB2, 
providing evidence to suggest that endothelial ephrinB2 facilitates monocyte 
transmigration. This is in agreement with previous reports indicating that MCP-1-
stimulated transmigration of monocytes or murine J774 macrophage cells is 
disturbed when ephrinB2 reverse signaling is blocked by monomeric ephrinB2 or 
by endothelial cells overexpressing the truncated cytoplasmic domain of ephrinB2 
[124, 139]. 
 
4.1.3 EphB2 induces ephrinB2 association with intercellular junction 
proteins and VE-cadherin internalization in endothelial cells 
In addressing the mechanisms through which ephrinB2 supports monocyte 
transmigration, we investigated the subcellular distribution of ephrinB2 in a 
confluent HUVEC monolayer. Consistent with the previous study, the present 
results revealed that ephrinB2 was restricted in the cell borders and partially 
colocalized with PECAM-1 [139, 141]. However, in quiescent endothelial cells, 
such as EC/SMC coculture spheroids in vitro or umbilical cords in vivo, ephrinB2 is 
expressed on the luminal surface of endothelial cells [141]. 
In order to explore the impact of EphB2 on the activation of endothelial cells, 
HUVECs were exposed to EphB2-overexpressing mouse myeloma cells that 
mimic the characteristic of monocytes. This stimulus enhanced the association of 
endothelial cell ephrinB2 with intercellular junction proteins, such as PECAM-1, 
VE-cadherin, and ZO-1. This is partly compatible with previous findings indicating 
that EphB4, which specifically binds to ephrinB2, triggers the translocation of 
ephrinB2 from cell surface to the junctions where it associates with PECAM-1 [139, 
141]. Moreover, displacement of VE-cadherin from cell junctions was observed in 
response to EphB2/Fc treatment. This is a critical process for loosening adherens 
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junctions and thereby favoring leukocyte transmigration [35]. However, the 
mechanism by which EphB2 induces VE-cadherin displacement is not clear yet, 
but it might result from endocytosis of the EphB/ephrinB complex and together 
with its surrounding plasma membranes into ephrinB- or EphB-expressing cells in 
case of cell contact [89]. For instance, EphB4 stimulation leads to the 
EphB4/ephrinB2 complex endocytosis, accompanied by the internalization of 
VEGFR2 and VEGFR3 which is colocalized with ephrinB2, and this process is 
crucial for VEGF signaling [91, 92]. Moreover, it is well-known that VEGFR2 
codistributes with VE-cadherin at cell contacts upon VEGF stimulation [158]. In 
addition, it has been suggested that VEGFR2 might form a protein complex with 
ZO-1, VE-cadherin and β-catenin in HUVECs [159]. Therefore, the results 
obtained in our study and previous findings support the idea of a protein complex 
comprising ephrinB2, VEGFR2 and cell junction proteins. Its 
assembly/disassembly and endocytosis might be controlled by EphB and/or VEGF 
treatment. This highlights the need for a more detailed analysis of EphB2-induced 
translocation of ephrinB2 to the cell border, leading to the association of ephrinB2 
with junction proteins and ultimately the internalization of this complex. 
 
4.1.4 EphB2 elicits Src-dependent PECAM-1 phosphorylation 
In this study, endothelial cell exposure to EphB2-overexpressing mouse myeloma 
cells increased Src activity, as the phosphorylation of Src at tyrosine residue 419 
was detected. This is in accordance with previous findings indicating that ephrinB 
reverse signaling is mediated by Src family kinases, which promotes ephrinB 
phosphorylation and initiates downstream signaling [103]. It is well-known that Src 
family kinases play a profound role in leukocyte transmigration, supported by the 
fact that their inhibitor PP2 is capable of blocking the transmigration [160]. This is 
partly due to Src being able to elicit the phosphorylation of molecules pivotal for 
leukocyte transmigration such as cortactin which regulates actin remodeling, and 
VE-cadherin whose phosphorylation leads to disassembly of adherens junctions 
[38, 39, 160]. Moreover, Src is critical for targeted recycling of membrane from the 
lateral border recycling compartment (LBRC) to the site of transendothelial 
migration, which is a prerequisite for leukocyte transmigration [161]. 
Furthermore, the present results demonstrated that EphB2 stimulation induced Src 
family kinases-dependent PECAM-1 phosphorylation, as PP2 diminished the basal 
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and EphB2-stimulated PECAM-1 phosphorylation. Leukocyte transmigration 
induced by a variety of mediators, such as hypoxia, glucose, LPS or crosslinking 
of ICAM-1, is associated with the phosphorylation of PECAM-1 in endothelial cells 
[144, 145, 162, 163]. However, phosphorylated PECAM-1 is not detectable during 
monocyte transmigration. This is probably due to the limited sensitivity of methods, 
rapid phosphorylation and dephosphorylation of PECAM-1 within a few seconds, 
and the low percentage of endothelial PECAM-1 (5-10%) that is involved in the 
interaction with leukocytes. Nevertheless, PECAM-1 phosphorylated on tyrosine 
residues appears to be restricted to the LBRC [161]. Specifically, tyrosine 663 is 
verified to be essential for leukocyte transmigration by regulating the target 
recycling of LBCR in endothelial cells [164]. 
In addition, the results from this study revealed that SHP2 phosphatase activity 
was reduced following EphB2 stimulation. It has been well-established that SHP2 
is physically associated with phosphorylated PECAM-1. Moreover, even though it 
is not well defined, some studies indicate that PECAM-1 is a substrate of SHP2. If 
this is the case, decreased SHP2 activity may protect the phosphorylation of 
PECAM-1 [165-168]. Inhibition of SHP2 has been linked to the disassembly of 
adherens junctions by enhancing tyrosine phosphorylation of VE-cadherin and by 
increasing RhoA activity, which eventually results in edema formation and 
endothelial cell dysfunction [169, 170]. 
Consequently, EphB2-stimulated VE-cadherin internalization, Src kinase activity 
and PECAM-1 phosphorylation in endothelial cells might be the mechanisms for 
supporting monocyte transmigration. However, it remains to be investigated 
whether ephrinB reverse signaling increases the phosphorylation of other Src 
kinase substrates, such as VE-cadherin and ZO-1, which may disrupt cell 
junctions and promote leukocyte transmigration. 
 
4.2 EphB2 evokes pro-inflammatory responses of endothelial cells 
4.2.1 EphB2 increases pro-inflammatory molecule expression in endothelial 
cells 
Next, it was hypothesized that ephrinB reverse signaling might modulate the pro-
inflammatory activation of endothelial cells and affect monocyte adhesion. Indeed, 
the results indicated that EphB2 stimulation elicited JNK-dependent upregulation 
of E-selectin expression. E-selectin promotes leukocyte rolling on the endothelial 
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cell surface by interacting with its ligands on leukocytes, such as PSGL1, CD44 
and ESL1 [171]. Furthermore, the results revealed that EphB2-induced increase of 
E-selectin expression was inhibited by the JNK inhibitor SP600125, suggesting 
that JNK acts in the downstream of ephrinB reverse signaling, which is consistent 
with earlier findings [115, 116]. In addition, our study indicated that VCAM-1 
expression was increased upon EphB2 stimulation, which mediates leukocyte firm 
adhesion by binding to integrin VLA-4 [26]. It also revealed that vWF was 
deposited on the surface of EphB2-treated endothelial cells, which acts as a key 
regulator of hemostasis and inflammation. Various pro-inflammatory mediators 
(e.g. histamine and endotoxin) elicit vWF secretion from endothelial cell Weibel-
Palade bodies to form string-like structure on their surface [172]. The deposited 
vWF interacts with PSGL-1 and β2-integrins on leukocytes to mediate their rolling 
and firm adhesion [173, 174]. Also, vWF binding to platelet GPIb promotes stable 
interactions of platelets with endothelial cells and thus provides a sticky surface to 
allow the adherence of leukocytes and to subsequently activate them [148, 175]. 
Moreover, our results showed that GM-CSF expression was increased in EphB2-
stimulated endothelial cells. It is well-known that pro-inflammatory mediators 
trigger GM-CSF expression, and it plays a role in activating leukocytes, including 
regulation of their adhesion and enhancement of cytokine and superoxide release 
[150, 176-180].  
 
4.2.2 EphB2 promotes monocyte adhesion 
Furthermore, the present results showed that monocytic cells preferentially 
adhered to EphB2-prestimulated endothelial cells. This is partially in line with 
previous reports that ephrinB2 reverse signaling in endothelial cells and EphB4 
forward signaling in monocytes are both required for monocyte adhesion [139]. 
Monocytes preferentially stick to ephrinB2-rich endothelial cells of the aorta, rather 
than to ephrinB2-poor endothelial cells in the mesenteric artery, and this adhesion 
is inhibited by monomeric ephrinB2 or EphB4 [136]. Collectively, EphB2-stimulated 
reverse signaling promotes pro-inflammatory differentiation of endothelial cells, 
and subsequently enhances leukocyte adhesion. 
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4.2.3 EphB2 increases endothelial cell permeability 
Increased vascular permeability is associated with tissue edema and leukocyte 
extravasation [48]. In our study, EphB2 stimulation disrupted brain endothelial cell 
barrier. Similar effects of ephrinB1 reverse signaling have been reported in 
epithelial cells. In these cells, ephrinB1 physically interacts with claudin1/4 on the 
same cell membrane. When cell-cell contact occurs, claudin-induced ephrinB1 
reverse signaling increases paracellular permeability [181]. Exactly how EphB2 
modulates the endothelial barrier function is unclear but may involve three 
possible mechanisms. One mechanism is that EphB2 stimulates Src activity. 
Activation of Src disrupts endothelial cell monolayer integrity by the 
phosphorylation of VE-cadherin, MLCK and FAK, which results in cell junction 
disassembly and endothelial cell contraction [182-184]. Therefore, deletion of Src, 
either by inhibitors or genetic ablation, blocks mediator-driven increases in 
endothelial permeability [184]. Another possible mechanism is that ephrinB 
reverse signaling has been reported to increase RhoA/ROCK activity, which 
promotes endothelial cell contraction and loosens their intercellular contacts [113, 
117]. Finally, EphB2 induces the association of ephrinB2 with endothelial junction 
proteins, and this may affect the localization and function of these junction 
proteins. However, these possible mechanisms need to be investigated in detail in 
further studies. 
 
4.3 The impact of endothelial ephrinB2 on inflammatory models 
On the one hand, the binding of endothelial ephrinB2 with monocyte EphB2 
promotes monocyte diapedesis and induces forward signalling to activate 
monocytes [136]. On the other hand, this interaction elicits ephrinB reverse 
signaling, which is capable of promoting pro-inflammatory differentiation of 
endothelial cells and increasing permeability of the endothelial monolayer. To 
further investigate the functional role of endothelial ephrinB2 in inflammation in 
vivo, we utilized four different inflammation-associated models on inducible 
endothelial cell specific ephrinB2 knockout mice, and thus analyzed monocyte 
recruitment and inflammatory pathology. 
In TPA-induced ear edema and thioglycollate-elicited peritonitis, it was observed 
that endothelial ephrinB2 had no impact on monocyte infiltration and inflammatory 
response, which might be due to the localization of endothelial ephrinB2 and the 
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harsh pro-inflammatory condition. EphrinB2, as a determinant of the arterial 
endothelial cell phenotype, is not expressed in postcapillary venules where 
leukocyte diapedesis occurs during inflammation [22]. Moreover, both TPA and 
thioglycollate are extremely harsh stimuli to evoke inflammation. As a 
consequence, both models are suboptimal to study the impact of ephrinB2 which 
appears to have supportive rather than rate-limiting effects on the inflammatory 
process. Moreover, loss of endothelial ephrinB2 had no impact on plaque size and 
macrophage accumulation in the atherosclerosis model. This might be due to the 
insufficient deletion of ephrinB2 in the aorta, as a result of the limited expression of 
Tie2 promoter in endothelial cells of large conduit arteries. 
With respect to the hindlimb ischemia model, it has been reported that ephrinB2 is 
abundantly expressed in endothelial cells of remodeling collateral arterioles, which 
might play a role in arteriogenesis by limiting SMC migration and supporting 
monocyte recruitment. [124]. However, the present results indicated that deletion 
of ephrinB2 in endothelial cells had no impact on the growth of collaterals as well 
as perivascular macrophage accumulation which is a hallmark of arteriogenesis 
[15]. This may be due to the fact that monocytes originate from parallel venules 
but not collateral arterioles. A recent study has revealed that monocytes emigrate 
from neighbouring venules, and then migrate towards the remodeling collateral 
arterioles to support the progression of arteriogenesis. When the paired venule is 
ligated along with the feeder arteriole, monocyte recruitment is abolished [185]. 
Besides the limitations of the utilized models, the redundancy of ephrinB family 
members also has to be considered. EphB2 receptor is capable of binding to 
ephrinB1, ephrinB2 and ephrinB3 [113]. While ephrinB3 is not expressed on the 
endothelial cells, ephrinB1 might compensate for loss of ephrinB2 in endothelial 
cells of ephrinB2EC-iKO mice [157]. The redundancy among ephrinB family 
members has already been indicated in previous publications. T cells specific 
double null ephrinB1 and ephrinB2 mutant mice display impairment of immune cell 
development and functions. However, the single knockout of ephrinB1 or ephrinB2 
in T cells has minor effects [130-132]. Therefore, considering the limitations of the 
current models and a possible ephrinB1-dependent compensatory mechanism, the 
results cannot fully exclude a role of endothelial ephrinB2 in monocyte 
extravastion and inflammatory processes. 
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4.4 The role of endothelial ephrinB1 in inflammation 
4.4.1 EphrinB1 reverse signaling mediates EphB2-induced E-selection 
upregulation in endothelial cells 
As discussed before, EphB2 binds with ephrinB1 and ephrinB2 to induce reverse 
signaling in endothelial cells. Next, our study delineated that ephrinB1 reverse 
signaling was mainly responsible for EphB2-induced pro-inflammatory 
differentiation of endothelial cells. Loss of ephrinB1, but not ephrinB2, decreased 
EphB2-induced upregulation of E-selectin expression. This is further supported by 
applying EphB4, which specifically binds to ephrinB2 to induce ephrinB2 reverse 
signaling in endothelial cells. It indicated that an increase of E-selectin expression 
elicited by EphB4 was much less when comparing with EphB2 stimulation. These 
findings intrigued us to focus on the role of endothelial ephrinB1 in inflammation. 
 
4.4.2 Endothelial ephrinB1 expression is increased in inflammation 
EphrinB1 is required for embryonic development, as ablation of ephrinB1 results in 
perinatal lethality associated with defects in neural crest cell-derived tissues, 
incomplete body wall closure, and abnormal skeletal patterning [186]. In adults, it 
has been observed that ephrinB1 expression is upregulated in various cell types 
during different models of inflammation, and it also plays a role in promoting the 
release of inflammatory cytokines and regulating leukocyte migration [133-135, 
140]. Moreover, ephrinB1, expressed by arterial and venous endothelial cells, 
transduces reverse signals to promote capillary sprout formation and corneal 
angiogenesis [122, 187, 188]. To date, the effect of endothelial cell ephrinB1 
during inflammation is not known. In this study, endothelial ephrinB1 expression 
was enhanced under several inflammatory conditions. In the atopic dermatitis 
model, ephrinB1 expression was increased in endothelial cells during 
inflammation-associated angiogenesis. In line with this, TNFα, as a pro-
inflammatory cytokine, elicited upregulation of ephrinB1 expression in HUVECs. 
This is further supported by an ex vivo experiment, indicating that ephrinB1 
expression was elevated in endothelial cells of TNFα-stimulated murine femoral 
artery. With respect to ephrinB2 expression, it was unaffected in HUVECs in 
response to TNFα, which is consistent with previous findings using iris endothelial 
cells [189, 190]. Additionally, the results also showed that endothelial ephrinB1 
was strongly expressed in venules running in parallel to collateral arterioles 
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undergoing arteriogenesis. The venules are the zones where monocytes originally 
emigrate from [185]. Hence, these findings suggest that the upregulation of 
endothelial ephrinB1 may play a role in monocyte extravasation through its 
interaction with EphB2 in monocytes. 
 
4.4.3 Endothelial ephrinB1 promotes monocyte transmigration 
This study revealed that endothelial ephrinB1 facilitated monocyte transmigration 
through an endothelial cell monolayer. This is supported by the finding that MCP-
1-induced THP-1 cell transmigration was inhibited by knockdown of endothelial 
ephrinB1 expression. Exactly how ephrinB1 assists monocyte transmigration is at 
present unclear, but may depend on the association of ephrinB1 and endothelial 
junction proteins. Our results indicated that unlike ephrinB2, ephrinB1 did not 
physically interact with PECAM-1 in endothelial cells. Nevertheless, some previous 
publications have revealed that ephrinB1 is associated with tight junction proteins 
in different cell types to modulate their functions. For instance, ephrinB1 interacts 
with the claudin-5/ZO-1 complex at the lateral membrane in cardiomyocytes, which 
is essential for stabilizing cell morphology and cardiac tissue architecture [191]. 
EphrinB1 creates a complex with adjacent claudin1/4 in epithelial cells to regulate 
cell adhesion and paracellular permeability [181]. In addition to direct association 
with tight junction proteins, ephrinB1 is capable of regulating the distribution of ZO-
1 and Cingulin by interacting with scaffold protein Par-6. This process eventually 
affects tight junction formation [110]. These findings provide us with a hint that 
ephrinB1 may be related to adherens and/or tight junction proteins in endothelial 
cells. Its interaction with EphB2 may modulate the activation of these junction 
proteins (phosphorylation and/or internalization) and thereby controlling 
endothelial cell-cell contacts. However, this possibility needs to be further 
investigated. 
 
4.5 Summary of the effects of EphB/ephrinB during inflammation 
Taken together, inflamed tissues display an increased expression of ephrinB1 and 
ephrinB2 in endothelial cells of angiogenic capillaries, which bind to EphB2 
receptors expressed in monocytes. This ligand-receptor interaction plays a role in 
monocyte extravasation mediated by ephrinB reverse signaling in endothelial cells. 
EphrinB1 and ephrinB2 facilitate monocyte transmigration through the endothelial 
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cell monolayer. This might be due to EphB2 stimulated Src-dependent PECAM-1 
phosphorylation, VE-cadherin internalization and ephrinB2 association with 
junctional proteins (PECAM-1, VE-cadherin, ZO-1). Coevally, EphB2-stimulated 
reverse signaling upregulates E-selectin expression mediated by ephrinB1/JNK, 
enhances VCAM-1 and GM-CSF expression as well as vWF deposition, and thus 
reinforces monocyte adhesion. Furthermore, EphB2 stimulation disrupts the 
endothelial cell barrier function. Collectively, considering previous findings showing 
that EphB forward signaling stimulates the release of pro-inflammatory cytokines 
from monocytes [136], it is tempting to speculate that the EphB/ephrinB system 
may amplify pro-inflammatory responses by their bidirectional signaling in both 
endothelial cells and leukocytes. 
 
displacement of VE-cadherin
p-PECAM-1↑
permeability↑ 
(reverse signaling)                
E-selectin ↑
VCAM-1 ↑
GM-CSF↑
vWF ↑
(reverse signaling)                
Inflammation
MCP-1, IL-8
(forward signaling)
Src
P P
P P
PECAM-1/VE-cadherin
ephrinB2/B1
EphB-receptors
Monocyte
endothelial cell
 
Figure 30: Summary of EphB/ephrinB-mediated effects during inflammation 
Binding of monocytic EphB2-receptors to endothelial ephrinB-ligands triggers reverse signaling in 
endothelial cells, leading to monocyte adhesion and transmigration, as well as increased 
permeability of an endothelial cell monolayer. EphB2 forward signaling in monocytes promotes 
their activation. 
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4.6 Perspective 
Based on the aforementioned findings in this study, some questions need to be 
addressed in the future.  
1. What is the role of endothelial ephrinB reverse signaling in inflammation in 
vivo? This question could be addressed by using inflammatory models on 
inducible endothelial cell specific ephrinB1 and ephrinB2 double knockout mice to 
assess the progression of inflammation and leukocyte extravasation. 
2. Does EphB2 induce translocation of ephrinB1 and ephrinB2 in endothelial 
cells? Does EphB2 promote formation of a complex containing ephrinB and 
endothelial cell junction proteins? Does EphB2 regulate activation of junction 
proteins such as phosphorylation and internalization, resulting in loosening cell-cell 
contacts? Furthermore, These questions intrigue us to investigate the distribution 
and interaction of ephrinB and intercellular junction proteins upon EphB2 
stimulation in more detail. 
3. What are the downstream effectors of ephrinB reverse signaling in 
endothelial cells, that are responsible for EphB2-induced endothelial permeability 
and leukocyte diapedesis? Several candidates remain to be analyzed, for 
instance, MLCK, FAK, RhoA and ROCK activity. 
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